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ABSTRACT 
METAGENOMIC METHODS IN IDIOPATHIC AND IMMUNE DISEASES 
Erik Clarke 
Frederic D. Bushman 
Microbial involvement in disease has been long-established, but only recently has 
metagenomics–the study of entire microbial communities–been leveraged in disease 
research. Powered by advancements in sequencing technologies, metagenomics has been 
used to better understand a wide variety of diseases, especially in the gastrointestinal tract 
and other areas with high microbial activity. However, the extreme sensitivity of modern 
sequencing and lack of established best practices yields high error rates when used in 
settings with low microbial involvement. To realize the potential of metagenomic 
sequencing in disease research, we need new high-precision experimental and statistical 
methods that reach clinical standards of confidence. In this thesis, I describe our search 
for microbial signatures in sarcoidosis, an idiopathic disease with suspected microbial 
involvement. Through the use of novel experimental and statistical methods, we were 
able to eliminate confounding environmental factors and identify the enrichment of 
Cladosporiaceae fungi in sarcoidosis. I next describe a computational method to recover 
pathogen genomes from a sample containing mostly host DNA without the use of over-
sequencing or culturing. This method enables study of cryptic pathogen genomes and the 
ability to track genetic variants that may affect virulence or antibiotic resistance. Finally, 
I demonstrate the integration of metagenomic sequencing with immune repertoire 
sequencing in patients with severe combined immunodeficiency after gene therapy. This 
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study is the first to describe the changes in an immune-naïve microbiome that occur 
during the development of a new immune system. We see that the microbiome of these 
children shift from an abnormal state to one resembling healthy children in conjunction 
with their restored immunities. These studies lay out methods that improve the precision 
and utility of metagenomic sequencing for investigating idiopathic and immune 
disorders. 
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Chapter 1. Introduction  
1.1. A brief history of infectious disease 
The birth of germ theory 
The link between germs and disease seems obvious to us now, but it was actually a 
relatively recent (and contentious) development in human knowledge. For most of the 
last few thousand years, infectious disease was thought to be spread by miasma, or dirty 
air–a hypothesis that helped explain the transmissibility of disease in certain cases, but 
failed to translate into effective public health practices. As urbanization spread and 
diseases like cholera became more prevalent, water- or sewage-based transmission 
patterns played a large role in disease outbreaks. In a now-famous cholera outbreak in 
London, a physician named John Snow tracked each disease incident and concluded from 
their distribution that they originated from a public water pump. He correctly 
hypothesized that the water was contaminated and suggested the agent of contamination 
(what he termed “cholera poison”) had a cellular structure and was capable of 
reproducing (Snow, 1856).  
This hypothesis was part of an emerging “germ theory” of disease based on the 
groundbreaking work by Ignaz Semmelweis, Louis Pasteur and others that suggested that 
microorganisms, rather than miasma, were the source of infections and infectious disease. 
Joseph Lister’s adoption of this theory and promotion of antiseptic practices in surgery 
(and the consequent reduction in mortality) showed germ theory’s immediate 
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applicability to healthcare, but it was not until the work of Dr. Robert Koch that a 
conclusive link between a microbe and a human disease was first established. 
Establishing the germ-disease link 
Koch was the first to demonstrate the causative link between anthrax and Bacillus 
anthracis spores by purifying the bacteria from an affected sheep and using it to infect 
mice, who developed anthrax symptoms (Koch & Carter, 1987). Similar experiments 
using culture and reinfection lead him to uncover the cause of cholera (Vibrio cholerae) 
and tuberculosis (Mycobacterium tuberculosis) and conclusively demonstrate a link 
between microbes and infectious disease (Koch & Carter, 1987). This work also set the 
foundation for modern culture-based microbiology by improving culture and staining 
techniques, but most importantly it led to the development of what are now known as 
Koch’s postulates. 
Koch’s postulates are guidelines for establishing a causal link between an organism and a 
disease (Koch, 1876). They require a) the presence of the organism in all affected 
subjects and absence in unaffected subjects; b) the organism must be isolated and 
cultured from an affected subject; c) when introduced to an unaffected subject, the 
isolated organism should trigger the disease; and d) the identical organism must be 
cultured from the newly-diseased subject.  
Successes of Koch’s postulates 
The establishment of the germ-disease link and Koch’s postulates led to a revolution in 
medical microbiology as the causes of some of humanity’s most troublesome diseases 
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were uncovered. In this “Golden Age” of microbiology (Blevins & Bronze, 2010), 
bacteria causing diphtheria (1883), tetanus (1884), pneumonia (1886), plague (1894), and 
dysentery (1898), as well as many others (Table 1-1), were identified using the principles 
behind Koch’s postulates. These discoveries were essential in tracing disease vectors–
often involving fleas, rodents, or sewage–and establishing key elements of modern public 
health practices, sanitation, vaccines, and epidemiology. Later, the advent of antibiotics 
would provide the means to treat, rather than simply prevent, these diseases.  
Year Disease Organism Discoverer 
1877 Anthrax Bacillus anthracis Koch 
1878 Suppuration Staphylococcus Koch 
1879 Gonorrhea Neisseria gonorrhoeae Neisser 
1880 Typhoid fever Salmonella typhi Eberth 
1881 Suppuration Streptococcus Ogston 
1882 Tuberculosis Mycobacterium tuberculosis Koch 
1883 Cholera Vibrio cholerae Koch 
1883 Diphtheria Corynebacterium diphtheriae Klebs, Loeffler 
1884 Tetanus Clostridium tetani Nicholaier 
1885 Diarrhea Escherichia coli Escherich 
1886 Pneumonia Streptococcus pneumoniae Fraenkel 
1887 Meningitis Neisseria meningitidis Weischselbaum 
1888 Food poisoning Salmonella enteriditidis Gaertner 
1892 Gas gangrene Clostridium perfringens Welch 
1894 Plague Yersinia pestis Kitasato, Yersin 
1896 Botulism Clostridium botulinum van Ermengem 
1898 Dysentery Shigella dysenteriae Shiga 
1900 Paratyphoid Salmonella paratyphi Schottmüller 
1903 Syphilis Treponema pallidum Schaudinn, Hoffmann 
1906 Whooping cough Bordatella pertussis Bordet, Gengou 
Table 1-1 – Discoveries from the ‘golden age’ of bacteriology. 
Researchers who discovered the bacterial pathogens behind mankind’s most troubling diseases during the 
‘golden age’ of bacteriology. Adapted from Blevins and Bronze (2010). 
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1.2. Sequencing and its use in infectious disease 
Reaching the limits of culture-based investigations 
While the principles behind Koch’s postulates remain the gold standard for identifying 
pathogens, it became quickly evident that they were not universally applicable. Koch 
himself noticed the presence of M. tuberculosis and V. cholerae in subjects who did not 
demonstrate symptoms, violating the first postulate (and establishing the concept of an 
asymptomatic carrier). Another persistent complication is the fact that many organisms 
are not able to be grown in pure culture, and so the experimental design suggested by 
Koch (culture and experimental infection in an animal model) is inapplicable. 
There are any number of reasons why a pathogen might be unculturable. For instance, 
viruses require specific cellular machinery to reproduce, so culturing on cell-free medium 
is impossible. In other cases, the parasite may require coinfection with another organism 
for viability (Hepatitis D, for instance (Makino et al., 1987)). This lack of cultivability 
does not preclude these organisms from being pathogenic, however, so rigid adherence to 
Koch’s postulates would preclude investigators from understanding the diseases caused 
by these types of microbes. Adaptation around these limitations lead to the discovery of 
the viral causes of yellow fever (Sellards & Hindle, 1928), foot-and-mouth disease 
(Loeffier & Frosch, 1897), and polio (Landsteiner K, 1909), among many others. These 
advancements demonstrated a growing understanding of the range and diversity of 
pathogens. 
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One approach toward the investigation of uncultivable pathogens involves the use of 
nucleic acid sequencing. Sequence-based methods provide researchers with ways to 
identify pathogens regardless of their cultivability. Approaches such as PCR for specific 
marker sequences in target organisms are exquisitely sensitive and do not depend on the 
viability of the target organism (Josephson, Gerba, & Pepper, 1993). More complex 
methods, including whole-DNA shotgun sequencing, are able to recover the entire 
genome of a microbe (Anderson, 1981)–or even the genomes of all the microorganisms 
in a sample (Segata et al., 2013). These methods have revolutionized microbiology 
because they have allowed us to understand more fully the microbial world outside the 
petri dish. They have also advanced infectious disease research because their sensitivity 
enables us to uncover broad spectrums of pathogens that are not able to be cultured or 
otherwise identified. 
To formalize the use of sequencing methods in infectious disease research, Fredericks 
and Relman published an update to Koch’s postulates (Fredricks & Relman, 1996). The 
new guidelines were specifically crafted to avoid the requirement of cultivability in 
suspected microbes, as by the time that review was published, countless diseases had 
been linked to microbes that cannot be grown in pure culture, such as Whipple’s disease 
(the Tropheryma whippelii bacterium, (Relman, Schmidt, MacDermott, & Falkow, 
1992)) and Kaposi’s sarcoma (human herpesvirus 8, (Huichen Feng et al., 2007)). 
Notable differences between the Koch’s and Relman’s postulates, besides the de-
emphasis on cultivability, include reframing the presence or absence of the organism as 
the enrichment or depletion of nucleic acids from that organism; correlation between 
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sequence- and tissue-based methods such as staining or in situ hybridization; and 
identification of plausible methods of virulence (e.g. from related species or identified 
virulence factors). The Relman guidelines are significantly less rigid in their formulation 
than Koch’s postulates as well. For instance, the requirement of enrichment of nucleotide 
signals in affected tissues, rather than absolute presence/absence, reflects the 
understanding that many factors unrelated to the disease state may affect the appearance 
of microbial DNA, including environmental factors, presence as commensals, and 
reagent contamination. In total, Fredricks and Relman’s guidelines are given as flexible 
measures that should be assessed holistically, much as Koch’s postulates had to be later 
interpreted. The violation of multiple guidelines is possible even in established causal 
relationships and the authors emphasize that none of the rules are dogmatic. 
Successes using sequencing in etiologic agent detection 
Despite the incumbent difficulties in establishing microbe-disease links via sequencing, 
there have been a number of notable successes. In 1992, David Relman et al. established 
that Whipple’s disease was caused by a previously-unknown microbe by recovering 16S 
ribosomal RNA sequences from five patients with Whipple’s disease (Relman et al., 
1992). The organism, termed Tropheryma whippelii, had been seen in affected patients 
via microscopy since the first description of the disease but had resisted all culture 
efforts. Its association with the disease was thus well-known, and the target sequence was 
isolated from all five patients and none of the ten healthy controls. This long-term 
association of the cryptic microbe and the disease thus simplified the challenge of 
establishing causality. While the precise virulence mechanisms were not described in the 
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1992 paper, they noted that T. whippelii was related to other Actinomycetes bacteria 
including pathogenic mycobacteria, and potentially shared disease-causing 
characteristics. 
In 2008, Feng et al. (H. Feng, Shuda, Chang, & Moore, 2008) identified the virus that 
caused Merkel cell carcinoma (MCC) through the use of digital transcriptome subtraction 
(Huichen Feng et al., 2007). This technique uses a reverse transcription step to convert 
mRNA into cDNA prior to sequencing, and subsequently removes all human-related 
cDNA after sequencing. The remaining sequences are checked for homology to potential 
organisms of interest: in this case, they already suspected a viral etiology based on 
similarities between MCC and Kaposi’s sarcoma. The presence of a transcript with 
similarities to existing polyomavirus T antigen allowed the researchers to eventually 
uncover the complete viral genome using primer walking; this genome was then used to 
check transcripts from other MCC libraries and to design PCR assays to check other 
MCC samples. The rates of detection for the new polyomavirus (termed Merkel cell 
polyomavirus) were 80% in MCC tissue and 8% in healthy; this represents a significant 
shift from the strict presence/absence suggested by Koch’s postulates and a concordance 
with Fredricks and Relman’s more flexible guidelines. 
More recently, modern metagenomic sequencing was used to identify the pathogen in a 
case of neuroleptospirosis that had evaded diagnosis via normal methods (Wilson et al., 
2014). A patient that presented with severe but ambiguous symptoms that were initially 
suspected to be neurosarcoidosis after no pathogen was detected. Cerebrospinal fluid 
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(CSF) and serum was then shotgun sequenced and analyzed with SURPI, a rapid 
pathogen detection pipeline (Naccache et al., 2014). SURPI detected traces of 
Leptospiraceae bacteria in the CSF but not in the serum sample with coverage across 
3.8% of a leptospira genome. On this basis, the administering physicians decided to treat 
the patient for neuroleptospirosis and the symptoms resolved. Leptospiraceae is normally 
detected through a serological test for immune response, but due to peculiarities in the 
patient’s condition (severe combined immunodeficiency, immunoglobulin 
supplementation, etc), the serological challenge was negative. In many ways, the success 
in identifying the causative agent in this study was unusually fortuitous. Leptospira are 
uncommon enough in a hospital setting not to be likely environmental contaminants and 
pathological enough in nature to be a convincing agent. For diseases where the etiologic 
agent is uncharacterized, SURPI is not a valid option because it references existing 
databases- a flaw intrinsic to most of the current methods of sequence classification. If 
the organism was commonly commensal and pathogenic only by merit of a compromised 
immune system, it would also be difficult to discern from background levels of that taxa.  
Isolating microbial species for genomic analysis 
Identifying the etiologic agents in disease is rarely the final step in treatment and 
diagnosis. Virulence and pathogenicity of an agent is often linked to species- or strain-
specific variations that may be difficult to uncover using normal phylogenetic markers 
such as the 16S or ITS rRNA gene sequences (a method explained in more detail below). 
To fully understand the pathogenesis of an organism, the complete genome is desirable so 
that virulence mechanisms can be determined. However, genomes for most microbial 
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species are still missing or incomplete (Aggarwala, Liang, & Bushman, 2017; Brown et 
al., 2015; Hug et al., 2016).  
Traditionally the means to get a precise species- or strain-level genome is to isolate and 
culture the organism and sequence the isolate, but as described above, such culture-based 
approaches are frequently not applicable (Amann et al., 1990; Ghazanfar, Azim, & 
Ghazanfar, 2010; Schmeisser, Steele, & Streit, 2007). In the examples outlined 
previously, few of the etiologic agents were cultivable in pure culture. One way around 
this is to sequence the sample with sufficient depth to achieve complete coverage of the 
target genome (along with a large amount of background DNA) (Forde & O’Toole, 2013; 
Mardis, 2008). In cases where the genome is especially small, including viruses, 
enrichment using PCR techniques are viable options (Minot et al., 2013), but these 
techniques are difficult to scale up to normal prokaryotic and eukaryotic genomes. 
There have been significant improvements in the ability of shotgun metagenomic 
sequencing to identify strain-level variations in microbial communities (Alneberg et al., 
2014; Olm, Brown, Brooks, & Banfield, 2017; Scholz et al., 2016), but these efforts all 
face similar pitfalls. For some methods, the complete strain-level genome must be 
captured and added to the relevant databases. For instance, programs like StrainPhlAn 
(Truong, Tett, Pasolli, Huttenhower, & Segata, 2017) and PanPhlAn (Scholz et al., 2016) 
use strain-level reference genomes or species-wide “pangenomes” to profile 
metagenomic communities for those known strains. Other approaches that avoid the need 
for reference strains, such as CONCOCT (Alneberg et al., 2014) and MetaBAT (Kang, 
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Froula, Egan, & Wang, 2015), use pooled metagenomic libraries to construct strain-level 
genomes, but face challenges when the organism of interest is especially rare in the 
sample and are prone to chimeric misassembly of strain genomes. 
Methods such as selective whole-genome amplification (SWGA) (Leichty & Brisson, 
2014) allow the enrichment of a target organism in a sample by exploiting differences in 
certain sequence motifs along the target and host DNA. By using primers targeted to 
sequence motifs more frequently appearing in the target than the background, and a 
highly-processive polymerase such as phi29, a researcher can preferentially amplify the 
target genome above the background genome. The resulting product is directly 
sequenced, but the resulting depth of sequencing required to reach sufficient genome 
coverage is substantially reduced. In this way, SWGA makes it easier to get precise 
variant-level information about an organism and allows the sequence variants that 
underlie its virulence or pathogenicity to be identified. Implementing SWGA for arbitrary 
genomes is not trivial, however, as the method described in the original paper for  the 
selection of effective primer sets is complex and error-prone. 
1.3. Metagenomics and the role of the microbiome in disease 
The human microbiome 
Infectious disease research focuses on the single causative agents of a disease: isolating 
and understanding particular pathogens and how to combat them. But it has been known 
for some time that the body is home to a vibrant community of microbial life. In 1673, 
Antonie Philips van Leeuwenhoek, an acclaimed microscopist, described seeing a variety 
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of tiny “animalcules” in samples of pond water and wood–making him the first human to 
see a bacteria. In 1861, Joseph Leidy described a flourishing community of microbes 
inside the guts of many animals. His work “A flora and fauna within living animals,” is 
one of the first descriptions of the microbiome (Leidy, 1861). 
We know now that humans share our bodies with trillions of commensal microorganisms, 
most of them bacteria and bacteriophage. The exact makeup of these communities vary 
by body site and functional characteristics (The Human Microbiome Project, 2012). They 
also play key roles in maintaining normal health. For instance, microbes in the gut 
facilitate nutrient absorption and digestion (Shreiner, Kao, & Young, 2015), help regulate 
the immune system (Arpaia et al., 2013), and may even affect mental state (Rieder, 
Wisniewski, Alderman, & Campbell, 2017). Microbes on the skin feed off of shedding 
skin cells and help prevent infections (SanMiguel, Meisel, Horwinski, Zheng, & Grice, 
2017), and microbes in the genital tract can hinder the acquisition of sexually-transmitted 
diseases, such as HIV (Buve, Jespers, Crucitti, & Fichorova, 2014).  
The microbiome’s role in maintaining health is also supported by evidence linking 
disordered communities to diseases including inflammatory bowel diseases (Gevers et al., 
2014), obesity (Le Chatelier et al., 2013), cardiovascular disease (Z. Wang et al., 2011), 
as well as lung and skin disorders (Charlson et al., 2010; Hannigan, Pulos, Grice, & 
Mehta, 2015; Kalan et al., 2016; Young et al., 2015). Thus, it is essential to understand 
exactly what makes a microbiome “healthy”, what functions they perform in their 
respective body sites, and how to alter their composition to prevent or treat disease.  
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The advent of metagenomic sequencing 
Traditional culture-based techniques are inefficient for metagenomic studies both because 
of the relatively small fraction of microbes that are cultivable, and because of the slow, 
low-throughput nature of culturing. In addition, phylogenetic characterization using 
morphology rather than genetic sequence leads to significant issues: some microbes may 
be morphologically identical but separate species, while other microbes may have wildly 
different appearances based upon factors such as environment or lifecycle stage– some 
fungi belong to two different families depending on their sexual stage due to exactly this 
problem (Underhill & Iliev, 2014). 
The concept of metagenomic sequencing is basically the adaptation of modern 
sequencing technologies to perform surveys of all the microbes present in a sample. 
Generally, metagenomic sequencing falls into two approaches: tagged marker sequencing 
or whole-genome shotgun sequencing. Tagged marker sequencing uses the amplification 
of conserved genetic regions in the microbial targets of interest to gather a picture of the 
microbial community in a sample. Examples of this include 16S rRNA sequencing for 
bacteria (Weisburg, Barns, Pelletier, & Lane, 1991), and internal transcribed spacer (ITS) 
rRNA sequencing for fungi (Schoch et al., 2012). These regions, or “markers,” contain 
hypervariable loci flanked by conserved sequences; in bacterial 16S rRNA these are 
regions V1-V9, and in eukaryotic ITS rRNA they are ITS1 and ITS2. These 
hypervariable loci are under significantly less selective pressure than their surroundings, 
and thus accumulate mutations at a higher rate (Gray, Sankoff, & Cedergren, 1984). The 
similarity of these regions between two taxa can therefore be used as a proxy for how 
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related the taxa are to each other. This also enables the cataloging of these regions into 
databases, so that microbes can be linked to their respective version of each marker. 
Thus, the amplification and sequencing of these marker regions, followed by similarity 
searches in databases like GreenGenes for 16S (DeSantis et al., 2006) and UNITE for 
fungal ITS (Koljalg et al., 2005), results in a picture of the bacterial or fungal 
communities in a sample. Tagged sequencing is generally low-cost and computationally 
straightforward. However, the results are limited to the microbial kingdom of choice, and 
even the selection of the variable region in the marker sequence can influence how 
sensitive the assay is at retrieving certain families of microbes (Meisel et al., 2016).  
The alternative approach to tagged sequencing is known as whole-genome shotgun 
sequencing. In this approach, the total nucleic acids in a sample are fragmented and 
sequenced without an intermediate amplification step, and the sequencing reads are 
matched to a database of microbial sequences (Quince, Walker, Simpson, Loman, & 
Segata, 2017). The benefits of this approach are that it is markedly less biased as it can 
capture DNA from any organism in the sample, and that it allows partial reconstruction 
of the genomes of the organisms, enabling functional characterization. Shotgun 
sequencing thus provides a more complete picture of the microbiome, but suffers from 
both high costs and analytic difficulty. In many shotgun sequencing experiments, a large 
fraction of the reads cannot be assigned to an organism due to the true originator of the 
read being absent from databases. And while the sequencing itself is relatively less 
biased, the databases themselves are not– some microbial orders are much better 
characterized than others (e.g. bacteria versus viruses or fungi). 
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As well as helping characterize the function and dysfunction of our microbiomes, 
metagenomic sequencing provides a key advancement in germ theory and our ability to 
associate microbes with disease. Sequencing the total DNA from healthy and diseased 
subjects enables detection of differentially-abundant microbial signatures and potentially 
illuminates cryptic agents in diseases that had evaded culture-based detection. 
Furthermore, the ability to gather the actual genetic sequences from these microbes 
provides the means to understand their pathogenic capacity. Genes that influence 
virulence, toxicity and resistance to antimicrobial compounds can be recovered from the 
metagenome and may one day form the basis of rapid sequencing-based clinical tests.  
Successes linking the microbiome to disease state 
Because the gut is the most well-characterized component of the human microbiome, 
many of the disease links we’ve associated with changes in the microbiome have to do 
with intestinal disorders. In particular, inflammatory bowel diseases such as Crohn’s 
disease have been closely linked to dysbiosis in the gut (Huttenhower et al., 2014; Lewis 
et al., 2015). Crohn’s disease is a complex disorder involving immune-mediated 
inflammation of the gut, especially the proximal colon and ileum. Instead of a single 
causative bacterium, researchers have found that structural changes, such as the loss of 
certain classes of bacteria and outgrowths of others, can be predictors of Crohn’s disease 
onset (Gevers et al., 2014; Haberman et al., 2014). Antibiotic usage and a decrease in 
bacterial diversity were also associated with disease severity (Lewis et al., 2015). 
Correction of dysbiosis through the use of fecal microbiome transplantation has shown 
promising results for Crohn’s disease (Ruben J Colman, 2014).  
 15 
 
Perhaps the most classic case of microbiome dysbiosis correlating with disease is in the 
case of Clostridium difficile infection. C. difficile is a commensal microbe in infants but 
rarely present in asymptomatic adults (Rousseau et al., 2012). Instead, infection is usually 
triggered by exposure to antibiotics, especially long-term use in chronic care facilities 
(Britton & Young, 2014). The alteration of the endogenous flora through antibiotics 
seems to provide an avenue for C. difficile colonization, and indicates that a “healthy” 
microbiome provides resistance to this pathogen. The exact mechanism by which the 
microbiome changes from being protective to permissive seems to be related to the 
production of bile salts and secondary bile metabolites (Britton & Young, 2014) (Britton 
2014). Certain bile acids trigger C. difficile spore germination, and their relative 
availability in the microbiome can be increased through the use of antibiotics. Thus, in 
the case of C. difficile, we observe a traditional infectious disease that is influenced 
strongly by the characteristics of the host gut microbiome. 
The use of the dysbiosis as a disease marker has also been demonstrated in preterm 
infants for necrotizing enterocolitis (NEC) (Pammi et al., 2017). In a systematic meta-
analysis, the authors found that increased levels of Proteobacteria and loss of 
Bacteroidetes and Firmicutes characterized a dysbiotic state that was a precursor to NEC. 
The correlation between gut bacteria and disease state indicate that microbiome 
monitoring and correction through the use of probiotics may be effective treatment for an 
otherwise difficult-to-treat disease. 
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Beyond disorders involving the gastrointestinal track, dysbiosis in the microbiome has 
also been linked to cardiovascular disease and mental health. In one study, Z. Wang et al. 
(2011) showed a link between the microbiome and production of phosphatidylcholine, a 
dietary metabolite correlated with heart disease. When the researchers dampened the 
abilities of the microbiome to produce this metabolite through the use of antibiotics, they 
saw a resulting reduction in disease rates, confirming the link between the metabolomic 
function of the microbiome and the disease. Recent studies have also linked the 
microbiome to mental health, mostly in animal models. For instance, in mice with a 
murine version of autism, researchers found they had abnormal microbiomes, and that 
addition of certain beneficial bacteria into their gut lead to less autistic-type behaviors 
(Hsiao et al., 2013). 
The microbiome and the immune system 
The links between microbiome structure and disease state often involve the immune 
system in some way (e.g. inflammation in IBD-type disorders). This is likely because the 
microbiome has been shown to have a regulatory and supplemental effect on the immune 
system itself (Arpaia et al., 2013; Atarashi et al., 2013; Kamada & Núñez, 2014). For 
instance, Arpaia et al. (2013) demonstrated that metabolites produced by the microbiome 
influence the development of pro- and anti-inflammatory regulatory T (Treg) cells. As 
these Treg cells are kept in balance in healthy individuals, it suggests that there is a 
homeostatic relationship governing the microbiome and immune system that can become 
disrupted in cases of dysbiosis.  
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The importance of the gut microbiota in maintaining immune homeostasis is in fact well 
documented (Guarner & Malagelada, 2003; Renz, Brandtzaeg, & Hornef, 2011; Walker, 
2013). For instance, hypersensitivity of the immune system to food-based allergens 
appears to be moderated by the gut flora (Guarner & Malagelada, 2003). This effect is 
determined by the co-development of the immune system with bacterial colonization of 
the gut in early life and takes place on the mucosal interfaces of the intestine and 
respiratory tract (Renz et al., 2011). In general, abnormal colonization or immune 
conditions early in life can lead to dysbiosis, allergy, or more dangerous immune 
disorders (Walker, 2013). 
Pitfalls in metagenomic sequencing 
Metagenomic sequencing thus has demonstrable clinical value in diagnosing and 
understanding a variety of diseases. However, there remain significant experimental and 
technological challenges associated with it that hinder clinical adoption. Perhaps most 
critical from a diagnostic or etiologic standpoint is modern sequencing’s susceptibility to 
false positives. This is partially due to the extreme sensitivity of sequencers and library 
preparation methods (Chin, da Silva, & Hegde, 2013). Consequently, both tagged and 
shotgun sequencing methods can retrieve extremely rare DNA molecules in a sample, 
including ones that are in fact environmental contaminants. Furthermore, sequencing is 
agnostic to the viability of the source material: it does not matter if the DNA came from a 
living or dead organism (Emerson et al., 2017). Because DNA is stable at room 
temperature, sterilization techniques kill contaminating microbes but allow their genetic 
material to persist. Microbial DNA has been regularly recovered from laboratory 
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reagents, for instance (Kim et al., 2017; Salter et al., 2014) and on sterilized hospital 
instruments. The combination of ambient DNA and the sensitivity of sequenced-based 
techniques means that it is extremely common to recover contaminant DNA in 
metagenomics.  
In studies where the goal is to find differentially-enriched microbes in disease, or to 
determine whether a pathogen is present or not, this contaminant DNA can be a 
significant confounder. A microbial signature may appear enriched in one disease state 
over another due only to differences in storage or handling of the samples. Similarly, 
sequences from a pathogen may appear in idiopathic disease samples, but only be leftover 
DNA clinging to sterilized hospital equipment. To prevent this, the researcher may 
employ methods of isolating only DNA from viable organisms such as those described in 
Emerson et al. (2017), but in many situations collection and storage procedures could kill 
all the microbes in the sample before workup (such as with formalin fixation). In 
addition, such methods may bias what is recovered through the metagenomic assay. 
Regardless of how the viability of the microbes is considered, it is critical to collect 
appropriate reagent and environmental controls to at least understand the contamination 
profile of the experiment. 
A number of recent studies have described microbial signatures (or even entire microbial 
communities) in parts of the human anatomy generally considered to be sterile in healthy 
individuals, including the brain, placenta and in semen (Aagaard et al., 2014; Branton et 
al., 2013; Hou et al., 2013). Without dismissing these results, it is highly possible that 
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these microbes came from any number of contaminating sources, including equipment, 
reagents, or nearby high microbial-load areas such as the mouth or genital tract. All too 
often, metagenomic studies do not include or show contamination controls, making it 
hard to assess the validity of their results. In a follow-up study to confirm the presence of 
microbes in placenta, for instance, Lauder et al. (2016) were unable to see any difference 
in microbial signatures between placenta samples and reagent controls. Significant work 
needs to be done from an experimental standpoint before metagenomic sequencing can 
reach clinically-acceptable levels of confidence. 
1.4. Motivations for this thesis 
In this thesis, I describe a series of studies that apply metagenomic sequencing to 
idiopathic and immunological diseases. My aim is to both provide insights into the target 
diseases and to demonstrate novel experimental methods that increase sequencing 
precision and sensitivity. 
New tools for the identification of etiologic agents 
In Chapter 2, I present our efforts to find an etiologic trigger for sarcoidosis, an extensive 
metagenomic study with broad clinical applications. This is the most comprehensive look 
at microbial signatures in sarcoidosis to date: we used 16S, ITS, and virome sequencing, 
as well as shotgun sequencing, in 732 distinct samples over three body sites. We 
uncovered signatures of a fungus in the Cladosporiaceae family that were enriched in 
sarcoidosis lymph nodes across two sample cohorts, suggesting a potential etiologic 
trigger. In addition, this study used a novel experimental design and statistical model that 
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allowed us to test for enrichment of a microbe in sarcoidosis both in relation to healthy 
controls and environmental background simultaneously. This experimental design is 
applicable to other clinical sequencing efforts and represents an advancement in low-
biomass metagenomic studies. 
Increasing sensitivity of pathogen genomics with swga 
In Chapter 3, I describe a new program called swga for designing primers for use in 
selective whole-genome amplification (SWGA). SWGA enables the recovery of a target 
microbe’s genome from a complex sample, such as a pathogen or parasite from a host-
derived sample. However, the effectiveness of the method relies on the selection of 
multiple primers that bind preferentially to the target’s genome over the background. 
Identifying an effective primer set is a computationally challenging task that originally 
involved a lot of manual trial-and-error. The program I describe in this chapter uses an 
approach derived from graph theory to establish compatible sets of primers for SWGA 
and evaluates their binding characteristics in arbitrary host/target genomes. I demonstrate 
how the program and method drastically reduce the sequencing costs for genome 
recovery of a variety of targets, including Mycobacterium tuberculosis and Plasmodium 
falciparum in humans and Wolbachia pipientis in Drosophila.  This program represents 
an advancement in infectious disease research by enabling researchers to recover the 
genomes of pathogens that are rare or uncultivable in primary samples. These recovered 
genomes can then be used to perform population genetics and understand disease 
outbreaks, or to model genetic variations that affect pathogenicity.  
 21 
 
Characterizing immune system and microbiome dynamics in SCID 
Finally, in Chapter 4, I integrate metagenomic sequencing to characterize the 
development of the microbiome in children with severe combined immunodeficiency 
(SCID) after gene therapy. These children are born without an immune system, but are 
still colonized by microbes, free of interference from the immune system. After gene 
therapy, however, the immune system “comes online” and through longitudinal 
metagenomic sequencing, we can observe how the new immune system and microbiome 
interact. To characterize the developing immune system, we used sequencing of the CD3 
region of the TCR-beta locus in circulating T cells. This allowed us to see clonal 
outgrowths that suggested the immune system was responding to extant microbiota and 
correlate T cell dynamics with microbiome changes. Finally, sequencing of gene therapy 
vector integration sites in the same samples allowed us to estimate the minimum number 
of cell divisions required to progress from a lymphopoietic progenitor cell to a circulating 
T cell, increasing our understanding of human immune development. 
Taken together, these studies improve our understanding of microbes in disease, provide 
novel methods for identifying and characterizing pathogens, and help understand the 
interactions between the immune system and the developing microbiome.  
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Chapter 2. Microbial lineages in sarcoidosis: A metagenomic 
analysis tailored for low microbial content samples 
The contents of this chapter have been previously published as:  
Clarke, E. L., Lauder, A. P., Hofstaedter, C. E., Hwang, Y., Fitzgerald, A. S., 
Imai, I., Biernat, W., Rekawiecki, B., Majewska, H., Dubaniewicz, A., Litzky, L. 
A., Feldman, M. D., Bittinger, K., Rossman, M. D., Patterson, K. C., Bushman, F. 
D., & Collman, R. G. (2017). Microbial Lineages in Sarcoidosis: A Metagenomic 
Analysis Tailored for Low Microbial Content Samples. Am J Respir Crit Care 
Med. doi:10.1164/rccm.201705-0891OC 
2.1. Abstract 
Rationale: The etiology of sarcoidosis is unknown, but microbial agents are suspected as 
triggers.  
Objective: We sought to identify bacterial, fungal or viral lineages in specimens from 
sarcoidosis patients enriched relative to controls using metagenomic DNA sequencing. 
Since DNA from environmental contamination contributes disproportionately to samples 
with low authentic microbial content, we developed improved methods for filtering 
environmental contamination. 
Methods: We analyzed specimens from sarcoidosis subjects (n=93), non-sarcoidosis 
control subjects (n=72) and various environmental controls (n=150).  Sarcoidosis 
specimens consisted of two independent sets of formalin-fixed, paraffin-embedded lymph 
node biopsies, bronchoalveolar lavage (BAL), Kveim reagent, and fresh granulomatous 
spleen from a sarcoidosis patient.  All specimens were analyzed by bacterial 16S and 
fungal ITS rRNA gene sequencing.  In addition, BAL was analyzed by shotgun 
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sequencing of fractions enriched for viral particles, and Kveim and spleen were subjected 
to whole-genome shotgun sequencing.  
Measurements and Main Results: In one tissue set, fungi in the Cladosporiaceae family 
were enriched in sarcoidosis compared to non-sarcoidosis tissues; in the other tissue set, 
we detected enrichment of several bacterial lineages in sarcoidosis, but not 
Cladosporiaceae. BAL showed limited enrichment of Aspergillus fungi.  Several 
microbial lineages were detected in Kveim and spleen, including Cladosporium. No 
microbial lineage was enriched in more than one sample type after correction for multiple 
comparisons.   
Conclusions: Metagenomic sequencing revealed enrichment of microbes in single types 
of sarcoidosis samples, but limited concordance across sample types.  Statistical analysis 
accounting for environmental contamination was essential to avoiding false positives. 
2.2. Introduction 
Sarcoidosis is a multisystem disease characterized by an aberrant immune response that 
results in inflammation and granuloma formation.  Sarcoidosis is believed to have an 
antigenic or inflammatory trigger that initiates the immune reaction in a susceptible host 
(E. S. Chen & Moller, 2014, 2015; Dubaniewicz, 2013).  Several susceptibility genes 
have been identified (Fingerlin, Hamzeh, & Maier, 2015; Fischer et al., 2014) but the 
trigger remains obscure.  Granulomatous inflammation is commonly seen in responses to 
microbial agents, as are other features of sarcoidosis immunopathology such as 
 24 
 
oligoclonal CD4 T cell expansion and TH1 polarization (E. S. Chen & Moller, 2014).  No 
microbial cause has been definitively established for sarcoidosis, but candidates include 
species of Mycobacterium (E. S. Chen et al., 2008; Drake et al., 2002; Dubaniewicz et al., 
2007; Song et al., 2005) , as well as fungi (Suchankova et al., 2015) and 
Propionibacterium acnes (Ishige, Usui, Takemura, & Eishi, 1999; Nishiwaki et al., 
2004), a common skin bacteria. 
The ability to detect rare or unculturable microbes has improved dramatically using deep 
DNA sequencing (H. Feng et al., 2008; Greninger et al., 2015; Kelly et al., 2016).  
Several studies have applied bacterial 16S rRNA gene sequencing to sarcoidosis, with 
differing results (Drake et al., 2002; Richter et al., 1996; Richter et al., 1999).  No prior 
studies have interrogated fungal lineages with tag sequencing, nor used shotgun 
metagenomic sequencing for comprehensive studies of total DNA or purified viral 
particles. 
We carried out an intensive metagenomic investigation of multiple sarcoidosis sample 
sets using 16S rRNA gene sequencing to capture bacteria, ITS sequencing for fungi, and 
whole-genome shotgun sequencing to characterize all microbes.  Samples (Table 2-1) 
include two independent sets of formalin-fixed, paraffin-embedded (FFPE) 
granulomatous tissue biopsies from newly-identified sarcoidosis patients and controls 
(sets A and B), bronchoalveolar lavage (BAL) from newly diagnosed untreated Stage 
II/III sarcoidosis patients and healthy controls (set C), We also interrogated a sample of 
the Kveim reagent (set D) (which is made from sarcoidosis-affected spleen and was used 
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historically for sarcoidosis diagnosis by intradermal injection and monitoring for 
granuloma formation (Klein et al., 1995; Siltzbach, 1961; Teirstein, 1998)), along with 
fresh granulomatous spleen from a sarcoidosis patient (set E). 
An often-underappreciated feature of sequence-based microbial detection is that at low 
levels of true signal, sequences can be dominated by microbial DNA from environmental 
sources introduced during sample collection, storage, DNA extraction or other steps 
(Lauder et al., 2016; Salter et al., 2014). This particularly confounds analysis of samples 
in which the authentic content of microbial DNA is low, such as lung bronchoscopies and 
tissue biopsies (Bittinger et al., 2014; Charlson et al., 2011; Robinson, Smith, Sengupta, 
Prentice, & Sandin, 2013; Salter et al., 2014). Even with the most careful preparation, 
however, there is often no way to eliminate environmental sequences completely, so 
further computational and statistical methods must be used to identify contamination.  
We thus used extensive environmental sampling and applied novel statistical modeling to 
minimize false positive calls.  By investigating several independent sample sets and 
tissue types, we were able to interrogate whether sarcoidosis-enriched sequences 
appeared consistently across sample sets. Some of the results of these studies have been 
previously reported in the form of an abstract (EL Clarke, 2015). 
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2.3. Methods 
2.3.1. Samples collected 
2.3.1.1. Archived tissue samples 
Two sets of FFPE sarcoidosis and control tissues were analyzed.  Set A (from Gdańsk) 
were mediastinal lymph nodes showing non-caseating granulomas typical of sarcoidosis, 
and negative by staining for acid-fast or fungal elements. Controls were mediastinal 
lymph nodes with normal or nonspecific reactive histology.  Set B (from Philadelphia) 
consisted of mediastinal nodes containing granulomas typical of sarcoidosis and negative 
by fungal and acid-fast stain.  Controls were histologically normal nodes from cancer 
staging procedures.  Stored specimens were retrieved and 10um cuts taken under aseptic 
conditions.  Paraffin block environmental controls were cut concurrently with tissue 
specimens.  For set A these were matched from the same block as tissue, while for set B 
they were not from the same block.  
2.3.1.2. Bronchoalveolar lavage (BAL)  
BAL fluid (set C) was obtained from subjects undergoing diagnostic bronchoscopy (from 
Philadelphia) for suspected new diagnosis of pulmonary sarcoidosis who had chest X-
rays consistent with parenchymal (Scadding stage II/III) involvement.  Subjects included 
here had sarcoidosis confirmed by standard criteria and exclusion of alternative 
diagnoses.  BAL was performed using standard clinical protocols.  Control BAL was 
obtained from healthy volunteers who underwent research bronchoscopy (Charlson et al., 
2011).  Prior to bronchoscopy, an environmental control (bronchoscope prewash) was 
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obtained as previously described (Charlson et al., 2011).  BAL and prewash were placed 
immediately on ice and stored at -80oC until analysis. 
2.3.1.3. Kveim and spleen tissue 
An aliquot of Kveim reagent ((Teirstein, 1998); set D) was analyzed that was prepared at 
Mt. Sinai Hospital (New York) for clinical diagnostic use as described (Chase, 1961) and 
stored under sterile conditions.  Sarcoidosis-involved spleen (set E) was obtained from an 
individual with longstanding disease (from Philadelphia), previously but not currently 
treated, who underwent splenectomy for symptomatic splenomegaly.  Tissue was freshly 
dissected from the organ and frozen at -80oC.  An aliquot of the saline used for tissue 
homogenization served as a matched environmental control.  
2.3.1.4. Human subjects  
Tissue samples were obtained from anonymized tissue archives. Bronchoscopy and 
spleen donor subjects provided written informed consent under IRB-approved protocols. 
2.3.2. Analysis 
2.3.2.1. Sequence analysis of 16S and ITS rRNA gene segments 
Details of extraction, amplification, Illumina sequencing and taxonomic assignment are 
in Supplement §2.7.1. The bacterial 16S ribosomal RNA gene was amplified using V1V2 
primers; this relatively short amplicon was chosen to maximize amplification efficiency 
for rare sequences from low microbial biomass samples (Charlson et al., 2011; Charlson 
et al., 2012). The fungal ribosomal RNA internal transcribed spacer ITS1 region was 
amplified using ITS1F/ITS2 primers (Bittinger et al., 2014; Charlson et al., 2012; Dollive 
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et al., 2012). Sequences were organized into Operational Taxonomic Units (OTUs) at 
97% identity. Statistical analysis was carried out at the individual OTU level, and at 
genus and family levels. 
2.3.2.2. Virome analysis 
Virome analysis was carried out on BAL and matched prewash specimens (Abbas et al., 
2016; Young et al., 2015). To enrich for viruses, fluid was pelleted and acellular material 
subject to size-exclusion concentration, followed by nuclease treatment to digest non-
encapsulated nucleic acids.  Nucleic acids were then extracted, and DNA subjected to 
whole genome amplification using GenomiPhi.  RNA was reverse transcribed to cDNA 
and PCR-amplified.  Resulting libraries were shotgun-sequenced, reads quality filtered, 
then annotated using a custom database we constructed that included all complete 
bacterial, fungal, archaeal and viral genomes in RefSeq release 79 (O'Leary et al., 2016).  
All non-viral reads were removed from consideration.  We found many reads annotated 
to viruses later determined to be either from reagents or mis-annotation of human reads 
(Abbas et al., 2016), which were therefore excluded.  Details are in Supplement §2.7.1.5. 
2.3.2.3. Whole genome sequencing 
DNA from sarcoidosis spleen tissue and Kveim reagent was subjected to whole genome 
sequencing (WGS) on an Illumina HiSeq.  Reads were quality-filtered, processed, and 
classified using Kraken (Wood & Salzberg, 2014) with our custom database (described 
above), with low-complexity regions masked before querying. Details are in Supplement 
§2.7.1.6.  The analytic pipeline is available at https://github.com/eclarke/sunbeam.  
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2.3.2.4. Accessing sequence data 
Sequence data are available in the NCBI SRA under BioProject ID PRJNA392272. 
2.3.2.5. Statistical analysis 
Code and a complete description are in Supplement §2.7.1.7. For sample sets A and C, 
which had paired environmental controls, we used the R package lme4 (Douglas Bates & 
Walker, 2015) to build a generalized linear mixed effects model (GLMM) to regress the 
number of reads of a taxa against the study group (sarcoid/healthy) and sample type 
(tissue/environmental control) (Supp. Figure 2-1).  Environmental levels of the taxa in 
each sample/control pair were captured as a random effect.  Enrichment was determined 
by the significance and directionality of the coefficient for the study group/sample type 
interaction term after fitting the model.  For sample set B, which did not have matched 
environmental controls, we used the R package DESeq2 (Michael Love, 2014) to 
determine enrichment.  
Because one could not predict a priori whether a putative sarcoidosis-associated 
microbial trigger would be a specific family, genus, species or even OTU, lineages were 
tested at the individual OTU level, then aggregated and tested at the species, genus, and 
family levels.  FDR correction was applied at each taxonomic level, and an FDR p-value 
cutoff of 0.1 was considered significant. While interrogating the data at each taxonomic 
level increased the risk of type I (false positive) errors, we considered this justified due to 
uncertainty over which taxonomic level might be linked to sarcoidosis and the 
exploratory nature of the study, and mitigated by the multiple independent sample sets.  
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Conversely, since requiring a lineage to reach FDR-corrected significance in multiple 
independent sample sets would increase the likelihood of type II errors, we also 
considered lineages that were significant after FDR correction in one sample set, but only 
significant before FDR correction in other sample sets. 
2.4. Results 
2.4.1. Sample sets studied 
We studied five sets of sarcoidosis samples and controls (Table 2-1). Two (sets A and B) 
were archival lymph node tissue from patients undergoing diagnostic biopsy, where the 
sarcoidosis tissue studied was histologically confirmed to show granulomas.  Set A 
included environmental control paraffin blanks matched to the individual tissue block and 
analyzed in parallel. BAL (set C) was from patients with untreated pulmonary sarcoidosis 
and healthy volunteers.  Reasoning that BAL would most likely reveal a microbial trigger 
early in the disease course with parenchymal lung involvement, we studied individuals 
newly presenting with radiological Scadding stage II/III.  Environmental controls 
matched to each sample were prewashes of the bronchoscope used to collect the BAL.  
We analyzed an aliquot of the Kveim reagent (set D), which is derived from sarcoidosis-
affected human spleen and used diagnostically by intradermal injection and monitoring 
for granuloma formation.  Since this suggests an immunological response to a triggering 
antigen (Klein et al., 1995), we hypothesized that Kveim reagent may contain DNA 
traces of an etiological microbe.  Finally, we tested fresh sarcoidosis-involved spleen (set 
E), paired with blank controls processed in parallel to model reagent contamination.  
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Sample 
Set Sample Type Study Group Samples Site Bacteria Fungi 
RNA 
viruses 
DNA 
viruses 
A 
Tissue Sarcoid 45 Gdansk 643 1180 N/A N/A 
Tissue Control 37 Gdansk 207 236 N/A N/A 
Paraffin only 
(paired) 
Environmental 
control 
82 Gdansk 465 1081 N/A N/A 
Blanks Reagent control 27 Gdansk 74 84 N/A N/A 
B 
Tissue Sarcoid 30 Philadelphia 5548 2136 N/A N/A 
Tissue Control 19 Philadelphia 2813 2703 N/A N/A 
Blanks Reagent control 5 Philadelphia 285 55 N/A N/A 
C 
BAL Sarcoid 16 Philadelphia 3105 25 1 85 
BAL Healthy subjects 12 Philadelphia 1604 13 1 40 
Prewash 
(paired) 
Environmental 
control 
24 Philadelphia 823 28 4 99 
Blanks Reagent control 4 Philadelphia 157 22 0 38 
D 
Kveim reagent Sarcoid 1 New York 1725 20 N/A 4 
Water 
Environmental 
control 
1 Philadelphia 1035 3 N/A 26 
E 
Spleen Sarcoid 1 Philadelphia 1156 19 N/A 3 
Saline wash of 
instruments 
Environmental 
control 
2 Philadelphia 408 2 N/A 31 
Water Reagent control 1 Philadelphia 1035 3 N/A 26 
Table 2-1. Sample sets studied. 
2.4.2. Set A: Lymph node tissue 
Microbial lineages detected in set A by bacterial 16S and fungal ITS rRNA gene 
sequencing are shown as stacked bar graphs (Error! Reference source not found.), with d
ominant taxa summarized in Supp. Figure 2-2.  Each tissue was paired with a control 
paraffin shaving from the same sample block. Lymph node and environmental control 
samples are thus plotted side-by-side.  In many cases, samples and paraffin controls 
appear similar. 
To investigate community structures in sarcoidosis and healthy lymph node samples, we 
calculated the UniFrac distance between each pair of samples and tested for clustering 
using PERMANOVA (Supp. Figure 2-3).  Bacterial communities were not significantly 
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different between sarcoidosis and non-sarcoidosis tissues (Supp. Figure 2-3A), but fungal 
communities were different (Supp. Figure 2-3B; p=0.027, R2=0.037).  We then asked 
whether community differences might be attributed to differential contamination. We 
performed the same PERMANOVA test on paraffin controls from sarcoidosis and non-
sarcoidosis samples.  No significant difference was detected in bacterial 16S data (Supp. 
Figure 2-3C), but we did detect a difference in fungal ITS data (Supp. Figure 2-3D; 
p<0.002, R2=0.091). Review of the specimen processing pipeline revealed that most 
sarcoidosis samples (31/45) were stored in a different building from non-sarcoidosis 
controls.  A PERMANOVA test of the effects of storage site on the paraffin 
environmental controls revealed a significant effect on fungi (p<0.00001) but not on 
bacteria.  The environmental fungi responsible for site-specific differences were mostly 
of the Aspergillaceae family (negative binomial test, FDR p-value=0.019; Supp. Figure 
2-2).  
To account for environmental admixture statistically, we designed a generalized linear 
mixed model (GLMM) that incorporated each sample’s matched environmental control 
(see Methods). In short, this approach uses the matched control to model the background 
levels of each taxa. Then, when testing for differential abundance of that taxa, the 
background levels are accounted for by a separate term in the regression rather than the 
study group term. We used this approach to test for differential abundance between 
sarcoidosis and healthy lymph node at the OTU, species, genus, and family level.  
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Among fungi, at the family level, Cladosporiaceae (within the Capnodiales order; Error! R
eference source not found.B) was significantly enriched in sarcoidosis (FDR p-
value=0.049). At the OTU level, no individual taxa were significantly enriched after FDR 
correction, but two Cladosporium OTUs were significant before FDR correction (p<0.05, 
FDR p=1).  The Cladosporiaceae fungal lineage is present both in tissue samples and 
paraffin blank controls, but is most abundant in sarcoidosis tissue (Error! Reference s
ource not found.C).  No bacterial lineages were significantly enriched in sarcoidosis 
after accounting for environmental contamination. 
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Figure 2-1. Dominant bacterial and fungal orders in lymph node (A). 
The major bacterial (A) and fungal (B) orders identified by 16S and ITS rRNA gene sequencing, 
respectively, are shown as proportions of total reads. Less common lineages are aggregated under “Other.”  
For each pair, the closed symbol (●) indicates the FFPE lymph node sample, while the open symbol (○) 
indicates a slice of blank paraffin cut from the same block to serve as an environmental control. Empty 
(white) bar charts indicate that the sample was either not available or had no detectable lineages. The 
difference in Cladosporiaceae reads between a sample and its environmental control are shown in (C). 
Closed circles represent samples with more Cladosporiaceae reads in the sample than the matched 
environmental control, while open circles represent samples in which the number of Cladosporiaceae reads 
were not greater than in the environment control. The abundances are shown as reads to more accurately 
reflect the input to the test, which used raw read counts as input. Normalization between differing 
sequencing depths was accounted for by modeling library size as a random effect for each sample (see 
Methods). 
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2.4.3. Set B: Lymph node tissue 
The dominant bacterial and fungal lineages in tissue set B are shown in Figure 2-2, with 
rank abundance plots in Supp. Figure 2-4. We compared community structure using 
UniFrac and PERMANOVA (Supp. Figure 2-5), and found differences in bacterial (but 
not fungal) populations between the sarcoidosis samples and healthy controls (p<0.05).  
We then tested for differentially abundant taxa at the OTU, species, genus, and family 
levels.  Numerous bacterial taxa were significantly enriched in sarcoidosis compared to 
control tissues, including three OTUs in the Corynebacterium (order Actinomycetales) 
genus (FDR p=1e-5, 0.064 and 0.067, respectively) and four OTUs in the 
Rhodocyclaceae family (order Rhodocyclales, FDR p=0.076, 0.003, 2e-05, and 0.005, 
respectively).  Other sarcoidosis-enriched bacteria were from the Sphinogomonadaceae 
family (order Sphingomonadales), the Comamonadaceaea and Oxalobacteraceaea 
families (order Burkholderiales), and the Moraxellaceae and Pseudomonadaceae families 
(order Pseudomonadales).  No fungal lineages were sarcoidosis-enriched in tissue set B 
after FDR correction, including Cladosporium (although fungi of this family do appear to 
be present in higher levels in the sarcoidosis samples; Supp. Figure 2-4).  Given the 
absence of paired environmental controls, these results are limited in isolation and serve 
mainly for comparison with other sample sets.  
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Figure 2-2. Bacterial and fungal lineages in lymph node (B). 
The major bacterial (A) and fungal (B) orders identified by 16S rRNA and ITS gene sequencing are shown 
as proportions of total reads. Less common lineages are aggregated under “Other.”  Seventeen samples 
failed to amplify any usable ITS sequences in B and are omitted. Blank paraffin controls matched to each 
tissue specimen were not available for these samples. 
2.4.4. Set C: Bronchoalveolar lavage 
We analyzed DNA from whole BAL for bacteria and fungi using 16S and ITS gene 
sequencing (Error! Reference source not found., Supp. Figure 2-6), along with 
matched bronchoscope pre-washes.  Analysis using UniFrac and PERMANOVA (Supp. 
Figure 2-7) showed no significant differences between sarcoidosis and control bacterial 
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communities.  To identify taxa enriched in sarcoidosis while accounting for 
environmental input, we employed the GLMM described above.  We found that the 
bacterial family Corynebacteriaceae (order Actinomycetales) was enriched in sarcoidosis 
before FDR correction, but no taxa were enriched after FDR correction.   
Fungal sequences in BAL were sparse (Error! Reference source not found.B), c
oncordant with previous reports on BAL fungal detections (Bittinger et al., 2014).  
However, the genus Aspergillus (within the Eurotiales order; Error! Reference source n
ot found.B) was enriched in sarcoidosis (FDR p=0.042). 
2.4.4.1. Virome analysis of sarcoidosis BAL 
We investigated the lung virome in sarcoidosis by generating virus particle preparations 
from acellular BAL and matched prewashes, and deep-sequencing both RNA and DNA.  
Initial inspection revealed abundant reads annotated as HHV6/HHV7.  These reads 
matched human simple sequence repeats (Abbas et al., 2016), and were therefore 
removed.  We also purged sequences that were present in blank controls and attributable 
to viral enzymes used as reagents, and thus likely reagent-derived.  Our approach was 
designed to detect both DNA and RNA viruses, but we did not recover any RNA viruses 
that did not likely originate from reagent contamination. 
The majority of remaining viral sequences were phages of the Siphoviridae and 
Iridoviridae lineages (Error! Reference source not found.C).  The data initially s
uggested a much richer population of viruses in sarcoidosis BAL than healthy controls.  
However, viral sequences in the sarcoidosis cohort’s prewash controls were also richer 
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than the control cohort’s prewash (Supp. Figure 2-8).  This difference is likely because 
sarcoidosis subjects underwent bronchoscopy in a clinical endoscopy suite, whereas 
healthy volunteers were sampled in a different facility used for research studies.  This 
suggests that each location contributed a different environmental background of virus 
sequences, likely originating in lavage saline or water used to rinse bronchoscopes after 
cleaning.  
We therefore used the same GLMM approach to account for environmental differences 
when testing for enriched viral species.  No viruses were sarcoidosis-enriched at any 
taxonomic levels tested.  Without accounting for environmental input, the enrichment 
analysis would have been confounded by differences resulting from bronchoscopy 
locations.  
 39 
 
 
Figure 2-3. Bacterial, fungal and viral lineages in BAL. 
The major bacterial (A) and fungal (B) lineages identified by 16S rRNA and ITS gene sequencing, and 
viral (C) lineages identified by shotgun sequencing of all nucleic acids in virus particle preparations, are 
shown as proportions of the total reads.  Data are shown at the order level for A and B, and the family level 
for C.  Less common lineages are aggregated under “Other.”  For each pair, the closed symbol (●) indicates 
the BAL fluid, while the open symbol (○) represents the prewash fluid for that scope. Empty (white) bar 
charts indicate that the sample was either not collected or had no detectable lineages. Three sample pairs 
failed to amplify any ITS sequences and are omitted from B. 
2.4.5. Sets D and E: Kveim reagent and sarcoidosis spleen 
We analyzed Kveim reagent and fresh spleen from a patient with sarcoidosis.  Three 
separate pieces of spleen were tested, along with controls to capture sequences from the 
environment.  Kveim, spleen and controls were subject to 16S and ITS sequence analysis 
(Figure 2-4A and B) and also shotgun whole-genome sequencing (WGS) (Figure 2-4C).  
WGS yielded mostly human sequences, which were removed; the remaining sequences 
queried for microbial annotations.  
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The predominant bacteria found by both 16S and WGS were in the Propionibacteriaceae 
family (within the Actinomycetales order), and were detected across all samples 
including controls.  Other ubiquitous taxa included Corynebacteriaceae and 
Pseudomonadaceae (of the Actinomycetales and Pseudomonadales orders, respectively).  
Some differences were seen between 16S and WGS analysis for other taxa, likely 
resulting from the relative representation of sequences within 16S and WGS databases.  
No taxa were present only in sarcoidosis samples and not environmental controls.  
Fungal detections were sparse in both ITS sequencing and WGS, and inconsistent 
between methods. Cladosporiaceae (order Capnodiales) was detected by ITS in one 
spleen sample, but not by WGS.  This may be due to a paucity of database genomic 
sequences for Cladosporiaceae, limiting detection in WGS annotation.  There was no 
consistent fungal detection in sarcoidosis samples versus controls. 
In the WGS data, we initially detected alignments annotated as Toxoplasma gondii in the 
Kveim and spleen samples. We also detected reads annotating to an unfinished 
Mycobacteria genome. However, these sequences were found to match human 
microsatellite simple repeats, and so were judged to be false-positives and removed 
(detailed in Supplement §2.7.1.5). This is an issue for WGS data but not for 16S or ITS 
analysis, as the untargeted approach allowed capture of low-complexity repeat DNA. The 
only viral reads detected were from bacteriophages and were also found in the controls, 
and thus inferred to be environmentally-derived. 
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Figure 2-4. Microbial lineages in Kveim and sarcoid spleen. 
The major lineages in sample sets D (Kveim) and E (sarcoidosis spleen) shown by sequencing. (A) Shows 
results from 16S sequencing, (B) shows ITS sequencing, and (C) shows results from whole-genome 
shotgun sequencing, after filtering as described in Supplemental Methods §2.7.1.6.  Less common lineages 
are aggregated under “Other”, including fungal detections in (C). 
2.4.6. Shared lineages 
No bacterial or fungal lineages were significantly enriched after FDR correction in more 
than one sample set.  To broaden our search, we examined lineages that were 
significantly enriched in one sample set after FDR correction, and queried their 
abundance in the other sets. Enriched lineages are summarized in Table 2-2. 
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Sample Set Kingdom FDR p < 0.1 non-FDR p < 0.05 
Tissue Set A 
Bacteria None None 
Fungi Cladosporiaceae OTU6408 (genus Cladosporium), Cladosporiaceae 
Tissue Set B 
Bacteria 
Many (113), including 
Corynebacterium and 
Rhodocyclaceae 
Many (252) 
Fungi None Many (149), including one Cladosporium OTU (OTU7142) 
BAL Set C 
Bacteria None 
OTU 104987 (Family Rhodocyclaceae), OTU 4301737 
(genus Porphyromonas), Corynebacterium, Neisseria 
Fungi Aspergillus Aspergillus 
Viruses None None 
Table 2-2. Summary of taxa enriched in sarcoidosis. 
Microbial taxa enriched in sarcoidosis lymph node and BAL over healthy controls. 
In tissue set A, fungi from the Cladosporiaceae family (order Capnodiales) were 
significantly enriched in sarcoidosis when tested as a group.  A single Cladosporium 
OTU (OTU7142) was enriched in tissue set B before multiple testing correction 
(p=0.042), though not the Cladosporiaceae family overall.  Cladosporiaceae were 
detected but not enriched in sarcoidosis BAL.  Finally, abundant Cladosporium reads 
were detected in one of three replicate spleen samples via ITS sequencing and not in the 
environmental controls, although it was not in WGS of spleen or Kveim. 
In tissue set B, three OTUs belonging to the Corynebacterium bacterial genus (order 
Actinomycetales) were significantly enriched in sarcoidosis.  While no individual 
Corynebacterium OTUs were enriched in other sample sets, the Corynebacterium genus 
was enriched in sarcoidosis BAL before FDR correction (p=0.02).  Corynebacterium 
were detected but not sarcoidosis-enriched in tissue set A, and also detected in Kveim 
and spleen, as well as environmental controls. 
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Also in tissue set B, multiple OTUs in the Rhodocyclaceae (order Rhodocyclales) 
bacterial family were significantly enriched.  A single Rhodocyclaceae OTU was 
enriched in BAL before FDR correction (OTU104987, genus Hydrogenophilus, 
p=0.009).  No Rhodocyclaceae lineages were detected in tissue set A, but appeared in 
both Kveim and spleen as well as controls from sets D and E. 
In BAL (set C), fungi in the Aspergillus genus (order Eurotiales) were significantly 
enriched in sarcoidosis.  Aspergillus was detected in tissue set A, but was not sarcoidosis-
enriched.  Numerous Aspergillus lineages were also detected but not sarcoidosis-enriched 
in tissue set B.  Aspergillus species were not detected in Kveim or spleen in sets D and E, 
but were found in the environmental and blank controls by WGS. 
2.5. Discussion 
This is the first study to interrogate microbial agents in sarcoidosis using a metagenomic 
approach combining bacterial and fungal sequence tag analysis, virome shotgun 
sequencing, and whole genome sequencing. We anticipated that a causal microbe would 
be present in low abundance, so rigorous consideration of potential contamination would 
be critical for distinguishing authentic from environmentally-derived sequences.  Our 
findings were inconsistent across the five sample sets analyzed (Table 2-1, Table 2-2), 
but do provide candidates for further validation, and strongly emphasize the importance 
of assessing environmental contamination.   
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Cladosporiaceae was significantly enriched in sarcoidosis specimens in tissue set A after 
adjustment for environmental admixture and multiple comparisons, and also appeared in 
several other sample sets, though not with comparable statistical enrichment. Fungi in the 
Cladosporiaceae family are extremely common in the environment (Ezike, Nnamani, 
Ogundipe, & Adekanmbi, 2016; Peternel, Culig, & Hrga, 2004), can trigger 
hypersensitivity pneumonitis and asthma (Chiba et al., 2009; Tham et al., 2017), and are 
capable of eliciting granulomatous inflammation (Robinson et al., 2013; Silva & 
Ekizlerian, 1985). This finding may warrant further investigation. 
In tissue set B, we detected multiple sarcoidosis-enriched taxa, but interpretation is 
limited by the lack of matched environmental controls.  Enriched taxa included several 
Corynebacterium OTUs, which were also sarcoidosis-enriched before FDR correction in 
BAL (set C).  Similarly, OTUs annotated as Rhodocyclaceae were significantly enriched 
in set B, and enriched before FDR correction in set C.  Corynebacterium are particularly 
interesting because they are known to elicit granulomatous responses in vivo (Nureki et 
al., 2007; Taylor, Paviour, Musaad, Jones, & Holland, 2003), although the association 
with sarcoidosis in this study was weak. 
In addition to histopathological similarities, mycobacteria have been linked to sarcoidosis 
by immunological responses and/or sequence-based detection (E. S. Chen et al., 2008; 
Drake et al., 2002; Dubaniewicz et al., 2007; Song et al., 2005). However, we did not find 
enrichment of mycobacteria in sarcoidosis.  Mycobacteria are difficult bacteria to isolate 
DNA from due to tough cell walls.  To ensure our methods were robust, we confirmed 
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detection via sequencing in known mycobacteria-infected tissue samples, and biological 
specimens spiked with avirulent M. tuberculosis (not shown).  We also found low levels 
of mycobacteria in many samples and environmental controls. This suggests that our 
methods are not inherently insensitive to mycobacteria, but that mycobacteria as a group 
were not enriched in these sarcoidosis specimens.  However, the 16S variable region 
amplified, V1V2, cannot distinguish between mycobacterial species, which precludes 
detection of species-level differences.  We also found that Propionibacterium acnes was 
a ubiquitous environmental agent, concordant with other studies (Mollerup et al., 2016), 
with no evidence of enrichment in sarcoidosis.  
Environmental admixture is an issue in any metagenomic survey and becomes 
increasingly important as the amount of authentic microbial content decreases (Salter et 
al., 2014).  Such sequences can be introduced from specimen collection and storage, 
DNA extraction kits, the processing pipeline, or even “barcode error” inherent in Illumina 
deep sequencing platforms that can allow low-level bleed-over in the sequencing process 
(Lauder et al., 2016). Most importantly in studies comparing subject groups, clinical 
samples collected at different times or locations may be contaminated with different 
environmental sequences.  This is especially problematic when taxa of interest may also 
be environmentally present, so simple subtraction of background lineages is 
inappropriate.  For example, sarcoidosis and healthy BALs were acquired in different 
locations and showed different background viromes.  For tissue set A, specimen storage 
location differed between study groups, which led to enrichment of environmental fungi 
in one group and not the other.  
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A key component of our approach is the generalized linear mixed model, which enabled 
us to capture and control the effects of differential environmental admixture without 
losing the ability to test for differential abundance in environmental taxa.  In tissue set A, 
without accounting for environmental input, a naïve enrichment analysis would have 
identified fungal species within the Aspergillus and Penicillium genera as sarcoidosis-
enriched.  The same is true for viruses in BAL (set C), which would have incorrectly 
identified greater phage populations in sarcoidosis.  The GLMM approach presented here 
would enable handling of potential confounding effects of environmental admixture in 
microbiome studies generally, and is particularly critical for specimens with low 
authentic microbial content, when coupled with appropriate matched environmental 
controls for each clinical sample. 
Our study has several limitations. We investigated microbes that might be enriched in 
sarcoidosis at time of diagnosis, which is the earliest time point feasible, but the time 
from actual disease onset is unknown, so an etiological trigger may no longer be present.  
Conversely, it is conceivable that microbial enrichment associated with sarcoidosis could 
be a consequence of the disease, rather than a cause.  Use of samples from distinct 
geographic locations would reveal shared lineages, but sarcoidosis triggers may differ 
geographically.  Additionally, any triggers may not be enriched in sarcoidosis subjects at 
all, but may be ubiquitously present, with disease determined mainly by host 
susceptibility factors.  Although we examined a total of 93 sarcoidosis and 72 non-
sarcoidosis specimens, plus 150 environmental controls (for a total of 738 sequencing 
reactions) the number of samples in any one set was modest. For the FFPE samples, 
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sensitivity may be lessened by damage DNA incurred by during the de-crosslinking step 
necessary to undo the formalin fixation (Campos, 2011). For our DNA virus methods, 
Genomiphi amplification may introduce bias towards short circular DNA due to rolling-
circle amplification, although this bias should be consistent across study groups. Finally, 
any primers chosen for tagged sequencing also have inherent biases and may be more 
sensitive to some microbes than others (such as with the V1V2 primers and 
Mycobacterium species, as discussed previously). 
In summary, application of metagenomic sequencing and analytic approaches tailored to 
low microbial-biomass samples did not identify a single causative agent but identified 
several candidate agents as sarcoidosis-enriched.  These include the Cladosporiaceae 
fungal family and Corynebacterium bacterial taxa.  The modest enrichment and limited 
concordance of these candidates in the sample sets precludes our ability to assert any 
causal relationship with sarcoidosis, but we believe these candidates may be of interest in 
future studies. More broadly, the model we present here increases the power of 
metagenomic studies in low microbial biomass samples, such as lung and tissue 
specimens, by allowing researchers to account for and test environmental admixture, thus 
avoiding potential spurious identifications. 
2.6. Acknowledgements 
We are grateful to subjects who generously volunteered for this study, to M. Padilla at 
Mount Sinai for the donation of Kveim reagent, to A. Ziober for assistance with tissue 
specimens, to W. Drake for avirulent mycobacteria, and to members of the Collman and 
 48 
 
Bushman laboratories for help and suggestions. This work was supported by the NIH 
grants U01HL112712 (Site-Specific Genomic Research in Alpha-1 Antitrypsin 
Deficiency and Sarcoidosis (GRADS) Study) and R01HL113252, and received assistance 
from the Penn Center for AIDS Research (P30AI045008) and the Penn-CHOP 
Microbiome Program. 
2.7. Supplemental Material 
2.7.1. Supplemental Methods 
2.7.1.1. Specimens analyzed 
Formalin-fixed paraffin-embedded (FFPE) sarcoidosis and control tissues in set A were 
from the Medical University of Gdansk (Gdansk, Poland) and tissue set B were from the 
Hospital of the University of Pennsylvania (Philadelphia, PA, USA).  Paraffin block 
environmental controls targeted a region of the block that did not contain tissue, and were 
cut at the same time as the tissue specimens.    
Bronchoalveolar lavage (BAL) fluid (set C) was obtained from subjects with Scadding 
stage II or III chest X-rays undergoing diagnostic bronchoscopy for a suspected new 
diagnosis of pulmonary sarcoidosis.  Subjects included here are those in whom 
sarcoidosis was confirmed based on standard criteria including transbronchial biopsy 
with noncaseating granulomas and exclusion of alternative diagnoses by culture and 
stains for fungi and mycobacteria. All subjects were newly-diagnosed and not previously 
treated. Non-sarcoidosis control BAL was obtained from healthy volunteers who 
underwent research bronchoscopy and have been described previously (Charlson et al., 
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2011).  An environmental control (bronchoscope prewash) was obtained prior to each 
bronchoscopy by suctioning 10 ml of lavage saline through the scope channel as 
previously described (Charlson et al., 2011).  
An aliquot of Kveim reagent (set D) was analyzed that was previously prepared at Mt. 
Sinai Hospital and validated for clinical diagnostic use as described (Siltzbach, 1961; 
Teirstein, 1998).  
A specimen of sarcoidosis-involved spleen (set E) was obtained from an individual with 
sarcoidosis who underwent splenectomy for symptomatic splenic enlargement.  
Histological examination subsequently confirmed granulomatous involvement of the 
spleen. Immediately following surgical removal, subcapsular tissue was dissected from 
the organ under aseptic conditions, transported in a sterile container on ice, cut into 0.1g 
pieces with sterile scissors and forceps under sterile conditions, then snap-frozen and 
stored at -80ºC. For analysis, one 0.1g piece of tissue was thawed, cut in thirds with a 
sterile scalpel, and each fragment subject to independent DNA extraction and analysis in 
parallel. To obtain an appropriate environmental control that reflected both specimen 
processing and sequencing steps, prior to tissue dissection an aliquot of saline (that later 
served as a vehicle for tissue processing) was used to gently rinse the scalpel that was 
subsequently employed for tissue dissection, and this was carried through the DNA 
extraction and sequencing pipeline.   
 50 
 
2.7.1.2. DNA purification 
DNA from paraffin-embedded, formaldehyde-fixed tissue samples (10um slices) was 
extracted using the Qiagen GeneRead DNA FFPE Tissue kit following manufacturer’s 
recommendations, except with the addition of a 10 minute, 95ºC incubation step during 
proteinase digestion to maximize DNA yield from hard-to-lyse fungi and other microbes, 
and increase DNA yield. For 16S and ITS sequencing, DNA from 1.8 ml of 
unfractionated BAL fluid and the corresponding scope prewashes was isolated using the 
PowerSoil DNA kit (MoBio, Carlsbad, CA), and included an additional 10 min, 95ºC 
incubation step as above. DNA and RNA isolation for virome sequencing is described 
below. For spleen, three sections of approximately 0.03g each were dissected from a 
larger 0.1g piece under sterile conditions, and DNA was isolated using the Qiagen 
QIAamp Pathogen UCP Mini kit. For Kveim reagent, 200ul aliquots of material were 
spun down at 10,000 RPM in a tabletop centrifuge for 10 minutes and the supernatant 
was discarded. The pellet was resuspended in SM buffer and extracted using the Qiagen 
QIAamp Pathogen UCP Mini kit. All extractions were performed in a BSL2+ hood after 
the workspace was treated with DNA remover and UV irradiation to remove 
environmental contamination. DNA was stored at -20oC. 
2.7.1.3. Sequence analysis of 16S and ITS rRNA gene segments  
Bacterial 16S ribosomal DNA was amplified using primers for the V1V2 16S region 
(Supp. Table 2-1) and PCR conditions as described previously (Charlson et al., 2012; 
Lauder et al., 2016). Each PCR reaction was carried out in duplicate or triplicate in 25ul 
reactions and pooled before sequencing. The PCR reactions were conducted using 
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AccuPrime Taq DNA Polymerase from Invitrogen and the pooled amplicons were 
sequenced on an Illumina MiSeq. Resulting sequence reads were processed using the 
QIIME 1.91 workflow (Caporaso, Kuczynski, et al., 2010). In brief, the reads were 
clustered into OTUs with 97% sequence similarity using UCLUST (Edgar, 2010) and 
aligned to full-length 16S sequences using pyNAST (Caporaso, Bittinger, et al., 2010). 
Taxonomic ranks were assigned using RDP Classifier (G. P. Wang, Ciuffi, Leipzig, 
Berry, & Bushman, 2007) with minimum 50% confidence. 
The fungal ITS1 region was amplified using ITS1F and ITS2 primers ((Dollive et al., 
2012; Gardes & Bruns, 1993), Supp. Table 2-1), with each sample individually barcoded 
using Golay barcodes. The PCR reactions were carried out in duplicate or triplicate with 
4ul of template, 0.4 ul AccuPrime Polymerase, 3ul of 10uM forward primer, 3ul of 10uM 
reverse primer, 2.5 ul Buffer II, and 12.1 ul PCR-grade water. The reactions were 
conducted using cycling parameters as follows: 94oC initial denaturation for 3 minutes; 
94oC for 45s, 56oC for 60s, 72oC for 90s (35 cycles); 72oC final extension for 10 minutes. 
The individual replicates were bead purified using Agencourt AMPure XP beads (1:1 
ratio), and then purified a second time with a 0.8 ratio to remove excess primer dimers. 
Amplicon concentration was assessed using Picogreen and product size checked on a 
BioAnalyzer. The final products were pooled for sequencing and bead-purified again at a 
0.8 ratio to remove further primer dimers. The sequencing was performed on an Illumina 
Miseq. After sequencing, the reads were processed using PIPITS (Gweon et al., 2015). 
Taxonomy was assigned using BROCC (Dollive et al., 2012) and all subsequent analysis 
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was performed in R. All synthetic DNA sequences used in this study are in Supp. Table 
2-1. 
2.7.1.4. Virome analysis 
To enrich for viruses in BAL and matched prewash specimens, the following steps were 
used: 1.8ml of BAL fluid was pelleted at 960g for 10 min and the acellular supernatant 
material then subjected to size exclusion concentration (100 kDa; Amicon). The filtered 
material was then nuclease treated to digest non-encapsulated nucleic acids.  Nucleic 
acids were extracted, DNA subjected to whole genome amplification using GenomiPhi, 
and RNA was transcribed to cDNA and PCR-amplified.  Details of these methods have 
been previously described (Abbas et al., 2016).  The resulting libraries were shotgun 
sequenced on an Illumina HiSeq 2500 using the Nextera XT DNA Library Preparation 
Kit (Illumina, San Diego, CA) with dual-indexed barcodes, and reads were quality 
filtered using Trimmomatic (Bolger, Lohse, & Usadel, 2014).  
Human reads were filtered by removing any that mapped to the human genome 
(GRCh38). Remaining reads were annotated using Kraken (Wood & Salzberg, 2014) 
using a custom database that included all complete bacterial, fungal, archaeal and viral 
genomes available in RefSeq release 79 (O'Leary et al., 2016). All non-virus reads were 
removed from consideration. We found many reads annotated to viruses later determined 
to be either from reagents or otherwise spurious, including mis-annotation of human 
reads, as we have previously reported (Abbas et al., 2016).  We excluded the following 
species: Enterobacteria phage M13, Enterobacteria phage T7, Enterobacteria phage phiX-
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174 sensu lato, Bacillus phage phi29, and Pseudomonas phage phi6, human herpesvirus 6 
and 7, and Shamonda virus. 
 
2.7.1.5. Additional quality control issues 
To minimize the impact of batch effects (Salter et al., 2014), a single lot of DNA 
extraction kits were used for all samples of a given type (including sarcoidosis, non-
sarcoidosis, and evironmental controls), and all samples of each set were combined and 
sequenced in a single sequencing run.  Because fixation can partially degrade DNA and 
subsequent downstream analysis (Campos, 2011), we used the Qiagen GeneRead FFPE 
kit, which includes an enzyme to correct C->T mutations that may occur. This kit does 
not address increased DNA fragmentation from fixation, but we expect these effects to be 
minimal due to the small length of the target V1V2 and ITS1 regions in 16S and ITS 
sequencing. 
2.7.1.6. Whole genome sequencing 
Sarcoid spleen tissue and Kveim reagent were analyzed using metagenomic whole 
genome shotgun sequencing. DNA was extracted using the Qiagen Ultraclean Pathogen 
(UCP) Mini kit following its recommendations for DNA isolation from tissue samples. 
Metagenomic sequencing was carried out on an Illumina HiSeq 2500 using the Nextera 
XT DNA Library Preparation Kit (Illumina, San Diego, CA) with dual-index barcodes. 
The reads from the metagenomic sequencing were then processed in the following steps: 
1) reads were quality-filtered, paired and adapter-trimmed using Trimmomatic (Bolger et 
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al., 2014); 2) human and phiX reads (used in sequencing library prep) were removed 
using bwa (Li & Durbin, 2009), and 3) reads were classified using Kraken (Wood & 
Salzberg, 2014) with a custom database built from all genomic sequences from RefSeq 
(release 79, (O'Leary et al., 2016)), with low-complexity regions masked before 
querying. The complete pipeline is available at https://github.com/eclarke/sunbeam.  
In initial analysis, reads containing short sequence repeats from human DNA were 
annotated to various species including Toxoplasma gondii and Mycobacterium spp. The 
short repeat sequences in these reads were also present in some draft genomes used to 
build our database, and were sufficiently complex to avoid masking by the NCBI dust 
program (Camacho et al., 2009) used on all database sequences. These annotations were 
judged to be false positives based on their presence in the human genome and the lack of 
any other reads aligning to Toxoplasma gondii and Mycobacterium spp.. To prevent 
further false positives, we used the RepeatMasker program (Smit, 2013-2015) to mask 
these repeat regions and re-ran the classification. The results presented here reflect 
classification after repeat masking. 
2.7.1.7. Statistical analysis 
In order to compare study group samples while accounting for the environmental 
controls, we developed a generalized linear mixed effects model (GLMM) with the 
following design. The presence or absence of a taxa was modeled using a binomial link 
function, and the fixed effects were study group (sarcoidosis or healthy) and sample type 
(BAL vs prewash, or FFPE vs blank paraffin). The random effects were the grouping pair 
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(i.e. the sample with its matched control) plus random effect for each individual sample. 
The inclusion of this latter random effect helped control overdispersion (Harrison, 2014) 
and account for varying library size between samples. The model was built using the 
‘glmer’ function in the R package lme4 (Douglas Bates & Walker, 2015). To determine if 
a taxon was significantly enriched, we looked at the significance and directionality of the 
coefficient on the study group and sample type interaction term. Specifically, the 
coefficient had to be positive in the sarcoidosis and non-environmental direction to be 
considered enriched in sarcoidosis over both the healthy and environmental background. 
The significance of the interaction coefficient was measured both by testing the model 
with and without the interaction term via ANOVA. The significance of the interaction 
coefficient was measured by ANOVA, comparing to an alternative model without the 
interaction term. Taxa appearing in less than 10% of the samples, for which the model 
failed to fit, or which had a negative interaction coefficient after fitting were discarded 
from further consideration. P-values from the remaining taxa were subjected to multiple 
testing correction using the Benjamini-Hochberg method (Benjamini & Hochberg, 1995). 
We set our FDR-corrected p-value threshold at 0.10 to prioritize finding potential hits. 
For tissue cohort B, we did not have matched environmental controls, and so the GLMM 
specified above was unnecessary. Instead, we used the R package DESeq2 (Michael 
Love, 2014) to assess enrichment of a taxa in sarcoidosis samples over healthy controls. 
DESeq2 uses a negative binomial distribution to fit taxon abundance in samples in a 
generalized linear model, but cannot model random mixed effects. The package provides 
p-value and multiple testing correction automatically, and for consistency we used the 
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same FDR threshold of 0.1. DESeq2 is one of the currently recommended methods for 
testing for differentially abundant taxa by the QIIME developers (Caporaso, Kuczynski, 
et al., 2010). 
In both the GLMM or the DESeq2 approach, we tested at a hierarchy of taxonomic ranks. 
After testing each individual OTU, we collapsed the counts according to species so that 
the reads of all OTUs belonging to the same species were summed together. We then 
tested each species from the same model, and repeated this process for genus and family 
level ranks. Our rationale for this was that etiologic agents may be multiple species or 
taxa within a higher group- e.g. a family of molds, or a number of closely related 
bacterial species. 
2.7.1.8. Data availability 
The code used for all analysis, including the specific model formulation, is available 
online at https://github.com/eclarke/sarcoid-microbiome-paper. Post-processed sequence 
data (after quality control, OTU formation, and taxonomic assignment) is archived at 
https://zenodo.org/record/825276. Raw sequence reads are archived with NCBI under 
BioProject PRJNA392272. 
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2.7.2. Supplemental Figures 
 
Supp. Figure 2-1. Illustration of statistical approach. 
Each taxa is considered individually. Background reads of the taxa from its environmental control (blue) 
are considered with the reads detected in the paired sample (red). The reads from a taxon are modeled using 
a binomial distribution link function in a generalized linear mixed model, and enrichment is determined by 
the magnitude and direction of the regression term corresponding to sarcoidosis samples when contrasted 
with healthy samples and environmental controls. A positive coefficient for the sarcoidosis + sample type 
interaction term indicates enrichment of that taxa relative to environment and healthy controls; statistical 
significance is assessed via ANOVA with a model lacking the interaction term between sample type and 
study group. The code describing the model exactly is available online at 
https://github.com/eclarke/sarcoid-microbiome-paper.  
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Supp. Figure 2-2. Dominant taxa in tissue samples (Set A). 
The dominant bacterial taxa (A) and fungal taxa (B) in sample set A are shown in the form of their median 
abundance in all samples (white lines) and 95% median confidence intervals (surrounding boxes). Lineages 
are grouped by their most specific taxonomic rank available. A differential enrichment of Aspergillus fungi 
is visible in the sarcoidosis samples and environmental controls, and enrichment of Cladosporiaceae is 
apparent in sarcoidosis lymph node.  
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Supp. Figure 2-3. Community differences in tissue samples (Set A). 
 60 
 
Distances between all pairs of samples were generated using generalized UniFrac (J. Chen et al., 2012; 
Lozupone, Lladser, Knights, Stombaugh, & Knight, 2011) with an alpha parameter of 0.5.  Principle 
Coordinate Analysis (PCoA) plots show relationships between bacterial communities in lymph nodes (A), 
fungal communities in lymph nodes (B), bacterial communities in blank paraffin (C), and fungal 
communities in blank paraffin (D). There were no significant differences in bacterial communities between 
sarcoid and healthy lymph node samples or their matched paraffin controls. There were significant 
differences in the fungal communities of sarcoid and healthy lymph node samples (p < 0.05), but these 
differences were also present in the matched paraffin controls (p < 0.01). 
 
Supp. Figure 2-4. Dominant taxa in tissue samples (Set B). 
The dominant bacterial taxa (A) and fungal taxa (B) in sample set B are shown in the form of their median 
abundance in all samples (white lines) and 95% median confidence intervals (surrounding boxes). Lineages 
are grouped by their most specific taxonomic rank available. 
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Supp. Figure 2-5. Community differences in tissue samples (Set B). 
Distances between all pairs of samples were generated using generalized UniFrac (alpha=0.5). Principle 
Coordinate Analysis (PCoA) plots showing relationships between bacterial communities (A) and fungal 
communities (B) in lymph node samples in sample set B. Significant differences were found in the bacterial 
communities of sarcoidosis and healthy lymph node (p < 0.05). 
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Supp. Figure 2-6. Dominant taxa in BAL samples (Set C). 
The dominant bacterial taxa (A), fungal taxa (B) and viruses (C) in sample set C are shown in the form of 
their median abundance in all samples (white lines) and 95% median confidence intervals (surrounding 
boxes). Lineages are grouped by their most specific taxonomic rank available.  
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Supp. Figure 2-7. Community differences in BAL samples (Set C). 
Distances between all pairs of samples were generated using generalized UniFrac (alpha=0.5). Principle 
Coordinate Analysis (PCoA) plots showing relationships between bacterial communities in BAL and 
prewash samples from set C. No significant differences were found between sarcoidosis and healthy BAL 
(panel A) or their corresponding prewash (panel B). 
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Supp. Figure 2-8. Differences in prewash viral populations. 
Viral populations differ between bronchoscope prewash samples taken just before bronchoscopy of healthy 
volunteers (left panel) and sarcoidosis subjects (right panel). Rows indicate the viruses detected, columns 
are separate samples. 
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2.7.3. Supplemental Tables 
Supp. Table 2-1. Oligonucleotide sequences used in Chapter 2. 
 Name Sequence Components 
Illumina 
MiSeq 16S 
V1-V2 
Amplification 
and 
Sequencing 
Primers 
Forward 
PCR 
amplification 
primer 
5'-
AATGATACGGCGACCACCGAGATCTACAC-
XXXXXXXXXXXX-TATGGTAATT-GT-
AGAGTTTGATCCTGGCTCAG-3' 
5' Illumina 
adapter, 12-base 
Golay barcode 
(X's), forward 
pad*, linker**, 
27F forward 
primer 
Reverse 
PCR 
amplification 
primer 
5'-CAAGCAGAAGACGGCATACGAGAT-
XXXXXXXXXXXX-AGTCAGTCAG-CC-
TGCTGCCTCCCGTAGGAGT-3' 
Reverse 
complement of 3' 
Illumina adapter, 
12-base Golay 
barcode (X's), 
reverse pad, 
linker, 338R 
reverse primer 
Forward 
sequencing 
primer 
5'-TATGGTAATT-GT-
AGAGTTTGATCCTGGCTCAG-3' 
Forward pad, 
linker, 27F 
forward primer 
Reverse 
sequencing 
primer 
5'-AGTCAGTCAG-CC-
TGCTGCCTCCCGTAGGAGT-3' 
Reverse pad, 
linker, 338R 
reverse primer 
Illumina 
MiSeq ITS1F 
and ITS2 
Amplification 
and 
Sequencing 
Primers 
Forward 
PCR 
amplification 
primer 
5'-
AATGATACGGCGACCACCGAGATCTACAC-
XXXXXXXXXXXX-TGCGGCCTGC-GT-
CTTGGTCATTTAGAGGAAGTAA-3' 
5' Illumina 
adapter, 12-base 
Golay barcode 
(X's), forward 
pad*, linker**, 
ITS1F primer 
Reverse 
PCR 
amplification 
primer 
5'-CAAGCAGAAGACGGCATACGAGAT-
XXXXXXXXXXXX-AGTCAGTCAG-CC-
GCTGCGTTCTTCATCGATGC-3' 
Reverse 
complement of 3' 
Illumina adapter, 
12-base Golay 
barcode (X's), 
reverse pad, 
linker, ITS2 
primer 
Forward 
sequencing 
primer 
5'-TGCGGCCTGC-GT-
CTTGGTCATTTAGAGGAAGTAA-3' 
Forward pad, 
linker, ITS1F 
primer 
Reverse 
sequencing 
primer 
5'-AGTCAGTCAG-CC-
GCTGCGTTCTTCATCGATGC-3' 
Reverse pad, 
linker, ITS2 
primer 
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Chapter 3. Swga: A primer design toolkit for selective whole 
genome amplification 
The contents of this chapter have been previously published in: 
Clarke, E. L., Sundararaman, S. A., Seifert, S. N., Bushman, F. D., Hahn, B. H., 
& Brisson, D. (2017). swga: a primer design toolkit for selective whole genome 
amplification. Bioinformatics, 33(14), 2071-2077. 
doi:10.1093/bioinformatics/btx118 
3.1. Abstract 
Motivation: Population genomic analyses are often hindered by difficulties in obtaining 
sufficient numbers of genomes for analysis by DNA sequencing. Selective whole-
genome amplification (SWGA) provides an efficient approach to amplify microbial 
genomes from complex backgrounds for sequence acquisition. However, the process of 
designing sets of primers for this method has many degrees of freedom and would benefit 
from an automated process to evaluate the vast number of potential primer sets. 
Results: Here, we present swga, a program that identifies primer sets for SWGA and 
evaluates them for efficiency and selectivity. We used swga to design and test primer sets 
for the selective amplification of Wolbachia pipientis genomic DNA from infected 
Drosophila melanogaster and Mycobacterium tuberculosis from human blood. We 
identify primer sets that successfully amplify each against their backgrounds and describe 
a general method for using swga for arbitrary targets. In addition, we describe 
characteristics of primer sets that correlate with successful amplification, and present 
guidelines for implementation of SWGA to detect new targets. 
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Availability and Implementation: Source code and documentation are freely available on 
https://www.github.com/eclarke/swga. The program is implemented in Python and C and 
licensed under the GNU Public License. 
3.2. Introduction 
Selective whole-genome amplification (SWGA) provides a means of obtaining sufficient 
numbers of genomes from a target organism to perform whole-genome sequence 
analysis, even in the presence of overwhelming DNA from other organisms (Leichty & 
Brisson, 2014). Difficulties in isolating a target of interest are common in microbial 
population genomics, which requires acquiring adequate genomic DNA from a target 
while limiting the amount of non-target DNA (Mardis, 2008). Often, the genomes of 
interest represent only a fraction of a percent of the total nucleic acids in a sample, and so 
direct sequencing is inefficient and expensive. Laboratory culture of the target microbe is 
the traditional solution, but many microbes replicate poorly or not at all in in vitro 
conditions (Amann et al., 1990; Ghazanfar et al., 2010; Schmeisser et al., 2007). 
SWGA allows sequence acquisition without culture of the target organism or extensive 
purification of target DNA. It achieves this by preferentially amplifying the target 
genome using a set of selective primers and phi29 polymerase-based multiple 
displacement amplification (MDA) (Dean et al., 2002; Leichty & Brisson, 2014). Since 
its introduction, this method has been used to study Wolbachia pipientis in Drosophila 
melanogaster (Leichty & Brisson, 2014), and to understand the evolution and drug 
resistance of Plasmodium falciparum (Guggisberg et al., 2016; Oyola et al., 2016; 
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Sundararaman et al., 2016) and Plasmodium vivax (Cowell et al., 2017). Further 
applications of SWGA to population genomics may help reconstruct epidemic 
transmission patterns, characterize patterns of inter-host viral transmission, detect escape 
from antimicrobial agents, and delineate the evolutionary dynamics of immune escape 
(Hume, Lyons, & Day, 2003; Luikart, England, Tallmon, Jordan, & Taberlet, 2003; 
Martínez et al., 2012; Nelson et al., 2008; Nunes et al., 2012; Stack, Murcia, Grenfell, 
Wood, & Holmes, 2012). 
Implementation of SWGA has been complicated by the difficulty in identifying an 
effective set of selective primers, as there are many constraints and degrees of freedom in 
the composition of potential primer sets. These primers must reflect DNA sequence 
motifs common in the target genome but rare in the background DNA. They also must 
have binding sites sufficiently near each other to enable the branching and displacement 
actions of the phi29 polymerase that are essential for MDA. A previously published 
method used a set of Perl scripts (Leichty & Brisson, 2014) to identify primers with the 
highest ratio of binding frequencies in the target genome versus the background DNA. 
However, choosing a set by the above method is suboptimal: for one, the primers may 
form heterodimers with each other or homodimers with themselves; they may be 
individually selective but in aggregate bind too frequently to the background DNA; or, 
they may bind to the target’s telomeric or mitochondrial DNA, and not be sufficiently 
evenly distributed across the genome. There are aspects of the primer sets that have an 
unknown effect on the efficiency of the reaction, including the annealing and melting 
temperature of the primer sequences, the evenness of the binding sites across the target 
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genome, and the density of binding sites. The Perl scripts mentioned above are unable to 
evaluate many of these criteria, requiring extensive manual effort and trial-and-error to 
create workable designs. 
Here we present swga, a program that identifies selective primer sets for a given target 
genome and background. swga evaluates all potential primer sequences and forms sets of 
valid primers that meet the above criteria. It automatically calculates a variety of metrics 
for each set that potentially affect the efficacy and selectivity of the reaction. These sets 
are then are ranked and presented to the user, enabling the selection of primer sets most 
likely to succeed. Nearly all operating parameters of the program are user-specifiable but 
initialized with reasonable defaults based on the target and background genomes selected, 
reducing the work needed to get started. 
We demonstrate the use of swga to design primer sets and test them on two biological 
systems: Wolbachia pipientis from infected Drosophila melanogaster, and 
Mycobacterium tuberculosis DNA spiked into human blood. For each system, we 
designed multiple primer sets to explore the effect of various aspects of the primer sets on 
reaction efficacy, such as primer melting temperature, binding density on the target 
genome, and the evenness of binding sites. These experimental results clarify the relative 
importance of each and allow us to describe an effective workflow for using swga. 
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3.3. Methods 
3.3.1. Program overview 
The swga program can be divided into four modules (Fig. 1). The user starts by defining 
the target and background sequences using swga init. At this point, a set of sequences 
can be supplied that define a priori where primers should not bind, such as a 
mitochondrial genome or plasmids (the ‘exclusionary sequences’). The swga count 
command then uses DSK (Rizk, Lavenier, & Chikhi, 2013) to identify all nucleotide 
sequences in the size range specified by parameters min_size and max_size that exist in 
the target genome and do not exist in the exclusionary sequences (if provided). These 
primers are used to populate a local SQLite database for later retrieval. The selectivity of 
these primers is determined by their frequency in the target genome versus the 
background DNA, so swga count saves the frequency that each primer appears in the 
target and background as well. Primers that appear extremely rarely in the target and 
overly frequently in the background (as defined by user-editable parameters, with 
defaults set by swga init), are not saved to help speed up downstream steps. Additionally, 
primers that would form internal hairpins or homodimers with themselves are omitted. 
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Figure 3-1. An overview of the swga workflow. 
An overview of the swga workflow. The program begins by counting all nucleotide sequences of length k 
(k-mer) in both the target and background genomes for a given range of k (e.g. 8–12 bp). The k-mers are 
then filtered by criteria that include the binding frequencies in the background and target genome, their 
melting temperatures, and the likelihood of hairpin or homodimer formation. The best k-mers are then used 
to form compatible sets, in which no k-mer would likely form a heteroduplex with any other in the set. 
These sets are then evaluated for multiple criteria including binding frequencies and evenness. The results 
can be exported into common formats for downstream use and visualization. 
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3.3.2. Primer filtering 
The command swga filter ranks and filters potential primers by their melting 
temperature, selectivity, and evenness of binding in the target genome. First, primers that 
bind too sparsely to the target genome (lower than parameter min_fg_bind) or too 
frequently to the background (max_bg_bind) are removed. Next, the melting temperature 
is approximated using nearest-neighbor thermodynamics (Allawi & SantaLucia, 1997) 
with corrections for mono- and divalent cations. Primers with melting temperatures 
outside the range defined by min_tm and max_tm are removed. The evenness of binding 
then is calculated by finding the Gini index (Gini, 1912) of the distances between each 
primer binding site on the target. The Gini index varies between 1 and 0, where 1 
represents extremely uneven and 0 represents perfectly even. A primer with a low Gini 
index has binding sites that are each separated by similar distances, whereas a primer 
with a high Gini index may reflect one where many of the primer binding sites are 
clumped together (e.g. on tandem repeat regions). Primers with Gini indices higher than 
max_gini are removed. Finally, primers are ranked by the ratio of target binding 
frequency to background binding frequency and those primers with the highest ratio are 
identified for downstream use (by default, this identifies the top 200 primers, and is 
modifiable via the max_primers parameter). The thresholds for each filter are user-
editable, and the swga filter command caches results so that it can be quickly re-run to 
explore different results. 
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3.3.2.1. Primer set evaluation 
The swga find_sets command is then used to find sets of compatible primers from the 
ones identified in the last step of swga filter. Brute force evaluation of all primer sets is 
computationally infeasible: given n primers and a set size of k, the total number of 
possible sets is (n choose k). With the default parameters of n=200 and  k=2−7, there are 
over 2.4×1016 possible sets. Fortunately, not all of these sets are usable for swga. A pair 
of primers are incompatible if they form heterodimers (calculated by the number of 
consecutive complimentary bases), or if one primer is a subsequence of another. swga 
find_sets calculates the pairwise compatibility of all selected primers and stores the 
results as a graph. In this graph, primers are vertices and compatible primers are 
connected with edges. The problem of finding compatible sets then reduces to a problem 
of finding sets of vertices in the graph that are all interconnected (a ‘clique’ in graph 
theory). swga also stores the average distance between binding sites on the background as 
a ‘weight’ on each vertex. This allows the program to prioritize cliques that have higher 
total weights, representing sets of primers that bind infrequently to the background. 
To find these cliques, the swga find_sets command uses a modified version of the 
program cliquer (Niskanen & Östergård, 2003). The branch-and-bound algorithm in 
cliquer is a computationally efficient way of finding cliques in a graph. We have 
extended the algorithm to find only cliques that meet certain criteria. By specifying the 
desired criteria a priori the algorithm can skip sets that do not meet the requirements and 
save computation time. These criteria include the minimum distance between binding 
sites in the background (min_bg_bind_dist) and maximum distance between binding sites 
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on the target (max_fg_bind_dist). In addition, the algorithm can explore a range of set 
sizes (min_size and max_size) in order to find valid sets. By specifying a broad range of 
set sizes, the algorithm is able to find sets with a broad range of characteristics 
independent of the number of primers. 
Primer sets that meet these criteria are further evaluated on metrics including the average 
and maximum distance between primer binding sites on the target genome and the Gini 
index of all binding sites in the set. These sets and their accompanying metrics are then 
saved. Even with the above optimizations, the number of valid sets can be quite large. For 
this reason, swga find_sets can be safely stopped after evaluating and storing a sufficient 
number of sets. In our usage, we generally stop after 1–5 million sets have been saved. 
3.3.2.2. Primer set output and visualization 
The saved primer sets can be explored and exported using swga export. This command 
allows the user to order the sets by any of the evaluated metrics, export all or some of the 
sets of interest to Excel-compatible formats, or export a set to a BedGraph or BedFile 
format for visualization in a genome browser (Kent et al., 2002) 
3.3.3. Empirical primer set testing 
To evaluate swga, we used it to design primer sets for amplification of W. pipientis DNA 
against a background of D. melanogaster and of M. tuberculosis against a background of 
H. sapiens. We evaluated primer sets on their ability to selectively and evenly amplify the 
target genome. 
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3.3.3.1. Designing primer sets for W.Pipientis 
We created four primer sets for W. pipientis against D. melanogaster, varying each by 
melting temperature range, selectivity, and evenness of binding sites on the target 
genome. We first initialized swga on the W. pipientis genome with D. melanogaster as 
the background, and ran swga count to store all potential primers. 
For the first two sets, we used swga filter with the ‘standard’ temperature range 
established in Leichty and Brisson (2014), and default in swga, of 15–45°C. This range 
we named Tm Low, or TmL. After running swga find_sets and storing 1 million sets, we 
used swga export to output the set with the lowest target to background binding distance 
ratio, which we called Set TmL/Selective. We then used swga export again to output the 
set with the lowest Gini index, which we called Set TmL/Even. 
The next two sets were designed with a higher melting temperature range. We re-ran 
swga filter with a Tm range of 35–55°C, which we named Tm High, or TmH. As above, 
we then re-ran swga find_sets on the new primers and chose the most selective and most 
even sets from the results. These are called TmH/Selective and TmH/Even, respectively. 
The complete parameter listing is included in Section §3.7.3. The primers belonging to 
each set are given in Supp. Table 3-1. 
3.3.3.2. Designing primer sets for M. tuberculosis 
We created ten primer sets for M. tuberculosis using swga. Our target genome was M. 
tuberculosis strain H37Rv (NC_000962.3) and our background was the human genome, 
version GRCh38. For this system, we ran swga filter with a temperature range constant 
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at 15–45°C, and imposed a maximum per-primer Gini index of 0.6. We stopped swga 
find_sets after storing five million sets and exported all of them to CSV format using 
swga export. The sets were filtered to only sets with mean distance between target 
binding sites <5000 bases. We selected ten sets with the most extreme combinations of 
mean target binding distance and evenness (via the metrics fg_dist_mean and 
fg_dist_gini, respectively). These sets we named Mtb1 through Mtb10. The distribution 
of these sets in the pool is visualized in Supp. Figure 3-1. In addition, we selected from 
the original five million the set with the highest Gini index (most uneven) and highest 
mean target binding distance as negative comparisons, named MtbUneven and 
MtbSparse, respectively. The full parameter listing is included in Section §3.7.3.2. The 
primers belonging to each set are given in Supp. Table 3-2. 
3.3.4. Selective whole-genome amplification and sequencing 
The Wolbachia-specific primer sets were tested on pooled genomic DNA extracted from 
10 Wolbachia-infected D. melanogaster (strain  Dmel\w118). Pooling was performed to 
eliminate inter-fly variability in Wolbachia infection levels, and each primer set was 
tested in triplicate using 40 ng of input DNA per reaction, except as noted for additional 
tests of the TmL/Even Wolbachia primer set. For consistency with the approach used in 
Leichty and Brisson (2014), the pooled genomic extract was digested with NarI (NEB, 
New England Biolabs, Inc., Ipswich, MA, USA) at 37°C for 30 minutes, in order to 
suppress mitochondrial amplification. This step is likely unnecessary in the general case 
because swga includes an option to omit mitochondrial sequences from primer formation. 
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Mycobacterium primer sets were tested on purified M. tuberculosis DNA (strain H37Rv, 
ATCC 27294D-2), diluted to 1% in human genomic DNA extracted from cultured 
CD4+ T cells. Primer sets were tested in triplicate. 
Selective whole-genome amplification was performed as previously described 
(Sundararaman et al., 2016), with slight modifications. Reactions were performed in a 
volume of 50 μL using input DNA, 3.5 mM total of SWGA primers, 1× phi29 buffer 
(New England Biolabs), 1 mM dNTPs and 30 units phi29 polymerase (New England 
Biolabs). Amplification conditions included a 1 h ramp-down step (35–30°C), followed 
by a 16 h amplification step at 30°C. Phi29 was then denatured for 10 min at 65°C. 
Amplified samples were purified using AmpureXP beads (Beckman Coulter), prepared 
for Illumina sequencing as described in (Kryazhimskiy, Rice, Jerison, & Desai, 2014), 
and sequenced on an Illumina MiSeq (150 bp, paired end). We also sequenced the 
unamplified pool to establish a baseline for amplification efficiency. Illumina-specific 
adapter and primer sequences were removed from the reads using cutadapt (Martin, 
2011). In both systems, reads were first aligned to the background (D. melanogaster or 
human) using smalt (Ponstingl & Ning, 2010). Unmapped reads were then mapped to the 
target genome (W. pipientis or M. tuberculosis, respectively), also using smalt. Analysis 
of sequence coverage of the target genome and sequencing rarefaction analyses were 
performed using R (R Core Team, 2017). All code used in the analysis and to generate 
the figures is available online at https://github.com/eclarke/swga_paper. 
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3.4. Results 
We used swga to design four primer sets for amplifying Wolbachia against a background 
of D. melanogaster, which tested the effect of melting temperature ranges, selectivity, 
and evenness. We designed twelve primer sets for amplifying M. tuberculosis against a 
background of human DNA with varying primer binding evenness and density on the 
target. Ten sets tested were various combinations of high density and evenness. Two, for 
comparison, were the most uneven and most sparse. For M. tuberculosis, we compared 
amplification using random hexamers (e.g. standard MDA) to the swga-designed primer 
sets. 
3.4.1. Evaluation of primer sets for W.pipientis 
The four primer sets for W. pipientis were designed with two different temperature ranges 
(TmL: 15–45°C, TmH: 35–55°C). From the sets identified in each temperature range, we 
chose the set with the highest selectivity, defined by the lowest target to background 
binding distance ratio (TmL/Selective and TmH/Selective). We also chose the sets with 
the most even distribution of binding sites (TmL/Even and TmH/Even). As a control, we 
included the primer set from Leichty and Brisson (2014). The composition and metrics 
for each of these five sets is shown in Table 3-1. 
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Table 3-1. Primer sets for Wolbachia. 
  Ratio  # Primers  Gini  Mean target dist  Mean bg. dist  
TmL/Selective  0.0544  9  0.654  5.33E+03  9.78E+04  
TmL/Evena  0.1050  7  0.537  6.85E+03  6.53E+04  
TmH/Even  0.0075  2  0.537  1.31E+04  1.73E+06  
TmH/Selective  0.0005  2  0.66  1.21E+04  2.43E+07  
Leichty 2014  0.0163  2  0.712  5.31E+03  3.25E+05  
 
Characteristics of primer sets chosen for selective whole-genome amplification of Wolbachia from infected 
Drosophila DNA. ‘Ratio’ is the ratio of average distance between binding distances in the target and 
background. aThe set that most effectively amplified Wolbachia. 
The pooled genomic DNA contained 4.7% W. pipientis DNA, as determined by 
sequencing of the unamplified control. We recovered ∼200 Mbp of sequence for each 
amplicon. The proportion of sequencing reads that were derived from W. pipientis was at 
least 2.5 times greater in all amplified samples than the sequencing reads from the 
unamplified genomic extract (Supp. Figure 3-2). We found that the primer sets with the 
higher melting temperatures (TmH/Selective and TmH/Even) yielded more Wolbachia 
reads as a total percentage, with some replicates as high as 77.8%. However, these primer 
sets failed to reach 10× coverage on even 10% of the W. pipientis genome (Figure 3-2). 
This was most likely due to uneven amplification of the target genome, as shown in 
Supp. Figure 3-3. 
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Figure 3-2. Sequencing effort required to cover Wolbachia genome. 
Selective whole genome amplification reduces the sequencing effort necessary to achieve at least ×10 
coverage across the W. pipientis genome. Each color represents an individual technical replicate; dashed 
lines represent the unamplified control. Lines above the unamplified control represent better sequencing 
efficiency in that they yielded greater coverage of the target genome with less sequencing effort. 
Sequencing 100 million bases from unamplified genomic DNA extracted from 10 flies resulted in 10-fold 
or greater sequencing coverage in only 2.8% of the W. pipientis genome. In contrast, the TmL/Even primer 
set resulted in 10-fold or greater coverage of 60–75% of the W. pipientisgenome with similar sequencing 
effort. This fraction was increased further to 72–91% when the TmL/Even primer set was used to 
amplify W. pipientis from 20 ng (rather than 40 ng) of total fly extract DNA (empirically, using lower total 
starting DNA can yield higher relative amplification when using phi29). The TmL/Selective primer set and 
the manually chosen set (Leichty & Brisson, 2014) improved W. pipientis sequence coverage relative to the 
unamplified sample. However, both of these sets failed to improve sequencing efficiency due an 
unevenness of coverage. The high Tm sets enriched only small portions of the genome and thus did not 
improve the genome coverage relative to the control. 
In contrast, the sets designed with the standard, lower melting temperature range (TmL) 
yielded more even coverage across the genome (Supp. Figure 3-3). The TmL/Even 
primer set, selected for having the most even distribution of primer sites across the 
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Wolbachia genome, gave high, even coverage across the target (Figure 3-3; Supp. Figure 
3-3). Moreover, the TmL/Even set reduced the sequencing effort required to achieve 10× 
coverage across 90% of the genome by 10-fold relative to the unamplified control (Figure 
3-2), extrapolating from the still-rising unamplified control’s rarefaction curve. While the 
final two sets—TmL/Selective and the Leichty set—provided more even coverage of the 
genome than the TmH sets, they ultimately did not outperform the unamplified control. 
The previously-published primer set from Leichty and Brisson (2014) yielded low total 
amplification efficiency (12.1–27.7%) and uneven coverage, while the TmL/Selective set 
had high amplification efficiency (50–60%) but similarly uneven coverage. 
We had originally expected that high numbers of primer binding sites in local regions of 
the genome would provide better coverage of that region. This was not seen in any of the 
sets tested (Supp. Figure 3-4). In each of the five sets tested, we did not detect a 
correlation between the number of primer binding sites and coverage. However, in primer 
sets with an overall higher density of binding sites on the target (as measured by a low 
average distance between binding sites), we had generally higher coverage across more 
of the Wolbachia genome (compare Figure 3-2 and Table 3-1). 
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Figure 3-3. Genome coverage by primer sets. 
Sequencing coverage of two swga-chosen sets, and the set from Leichty and Brisson (2014), across the W. 
pipientis genome. The depth of sequencing coverage per 1 Mb of sequencing effort (1 Mb * coverage 
depth/total bp sequenced) is shown for representative replicates of TmH/Even and TmL/Even (red lines) 
relative to the unamplified control (black lines). SWGA using the TmL/Even primer set improves depth of 
coverage across the majority of the W. pipientis genome by 10- to 100-fold, relative to the unamplified 
control. SWGA using the Leichty and Brisson (2014) (top panel) or TmH/Even (middle panel) sets also 
improve depth of coverage but over smaller regions of the genome, with the TmH/Even set resulting in high 
but localized amplification. Depth of coverage plots for all primer sets and replicates are shown in Supp. 
Figure 3-3. 
In summary, the primer set with the lowest Gini index and standard melting temperature 
(TmL/Even) was the best at selectively and evenly amplifying Wolbachia. While other 
sets provided a higher percentage of Wolbachia DNA (Supp. Figure 3-3), the overall 
coverage of these sets was low and amplification mostly occurred in specific regions 
(Figure 3-3). This suggests that evenness of primer binding sites on the target is a major 
factor in the efficacy of the primer set. 
3.4.2. Evaluation of primer sets for M. tuberculosis 
For M. tuberculosis, we restricted the primer pool to only those with a low Gini index 
(<0.6). We let the program identify five million primer sets and then selected only those 
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sets whose mean distance between binding sites on the M. tuberculosis genome was <5 
kb. From the resulting pool of primer sets, we selected ten sets with the most extreme 
combinations of primer set binding evenness and density to test the contributions of each. 
These ten will be referred to as our positive tests (Mtb1-10), and the distribution of these 
points on the total pool of sets is shown in Supp. Figure 3-1. We also selected the least 
selective set and the most uneven set from the five million set pool as negative controls 
(MtbSparse and MtbUneven, respectively). The composition and metrics for each of 
these 12 sets is shown in Table 3-2. 
Table 3-2. Primer sets for M. tuberculosis. 
  Ratio  # Primers  Gini  Mean target dist.  Mean bg. dist.  
Mtb6a  0.0057  7  0.501  1.95E+03  3.41E+05  
Mtb9a  0.0058  7  0.538  1.78E+03  3.05E+05  
Mtb4a  0.0062  7  0.512  1.88E+03  3.04E+05  
Mtb8a  0.0062  7  0.533  1.80E+03  2.92E+05  
Mtb7  0.0066  7  0.499  2.03E+03  3.09E+05  
Mtb2  0.0095  7  0.484  3.29E+03  3.45E+05  
Mtb5  0.0155  6  0.480  5.00E+03  3.22E+05  
Mtb1  0.0171  7  0.476  4.97E+03  2.90E+05  
Mtb3  0.0172  7  0.478  4.99E+03  2.90E+05  
Mtb10  0.0181  7  0.479  4.29E+03  2.37E+05  
MtbUneven  0.0140  2  0.623  1.14E+04  8.10E+05  
MtbSparse  0.0387  3  0.505  2.60E+04  6.71E+05  
 
Characteristics of primer sets chosen for selective whole-genome amplification of M. tuberculosis from 
human DNA, ordered by ratio. ‘Ratio’ indicates the ratio between the average distance between binding 
distances in the target and background. Primer sequences are listed in Supp. Table 3-2. aThe sets that most 
effectively amplified Mycobacterium using SWGA. 
The four sets with the lowest mean binding distance (sets Mtb4, Mtb6, Mtb8 and Mtb9) 
on the M. tuberculosis genome performed better than the unamplified controls, six other 
positive tests, both negative tests and the random hexamers (Figure 3-4 and Table 3-2). 
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These sets reached 1× coverage across 38–60% of the M. tuberculosis genome with 200 
megabases of sequence, while the remaining six positive tests did not perform better than 
the negative controls (Figure 3-4; Supp. Figure 3-5). These four sets yielded higher 
coverage across most of the Mycobacterium genome than the unamplified controls, while 
the remaining sets either only amplified certain regions or did no better than unamplified 
(Supp. Figure 3-6). Deeper sequencing of these four sets’ amplicons showed that the sets 
reached 10× coverage over 29–50% of the target by 1.5 Gbp of sequencing effort, with 
the unamplified controls only reaching 10× coverage on 2.5% of the target for the same 
sequencing effort (Figure 3-5). 
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Figure 3-4. Genome coverage using a range of set designs. 
Selective amplification of Mycobacterium using swga-designed sets that prioritized primer-level evenness 
and set-level binding density and selectivity. Curves indicate the percent of the target covered at 1X depth. 
Sets are ordered by the ratio of average distance between primer binding sites on the target to average 
binding distance on the background. The coloring indicates individual replicates, and the black dashed line 
indicates the unamplified control. The sets with the lowest ratios returned greater coverage of the target 
genome compared to unamplified controls than those with higher ratios, as shown by the rarefaction curves 
of these sets being higher than the dashed lines. 
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Figure 3-5. Deeper sequencing of M. tuberculosis. 
Deeper sequencing of four primer sets yields greater coverage of M. tuberculosis genome. The colored 
lines indicate individual replicates and the green dashed line is the pooled total. All four sets yield ∼10-fold 
increases in efficiency over the unamplified samples (black dashed line). The primer sets reach ×10 
coverage on between 28 and 50% of the target genome while the unamplified controls were at < 2.5% ×10 
coverage with 1.5 Gbp of sequencing. 
For Mycobacterium, we found that sets with smaller distances between primer binding 
sites on the target genome outperformed those optimized for lower Gini index. Nine out 
of the ten positive test Mycobacterium sets, including the four best sets, had lower Gini 
indices than the sets for Wolbachia. This suggests that after a certain threshold the Gini 
index becomes secondary to the primer binding site density. Therefore, pre-selecting 
primers with a low Gini index during swga filter and then choosing sets with high 
binding density in swga export allows the optimization of both attributes, and should 
yield effective primer sets. 
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3.5. Discussion 
Selective whole-genome amplification provides a way to preferentially amplify a target 
genome from a complex background. However, implementation of the SWGA method 
has been limited due to the difficulties in designing an effective set of primers. 
Assembling a primer set where all of the primers are compatible with each other, 
selective for the target genome, and rare in the background is a problem with many 
degrees of freedom. The swga program addresses this difficulty by automatically 
identifying and evaluating primer sets by specified criteria, allowing the user to select 
only those sets most likely to succeed in selective amplification of the target. 
We used swga to design primer sets for W. pipientis and M. tuberculosis that selectively 
amplified each in the presence of their host’s genome. These sets had varying binding 
evenness and selectivity for the target genome, allowing us to compare these attributes to 
the performance of each set. In addition, we demonstrated potential clinical utility of the 
swga program by amplifying DNA from the M. tuberculosis pathogen spiked into human 
blood. While in these experiments we used target/background pairs with clearly defined 
genomes, there is no reason the background cannot be a heterogenous mixture of DNA, 
such as stool or soil. In this case, the background could be approximated by whole-
genome shotgun sequencing of the mixture, and subtracting any reads belonging to the 
target, if present. 
Based on these results, it appears that primer binding evenness (as measured by the Gini 
index), primer set binding selectivity, and the density of binding sites on the target 
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genome each play an important role in the set’s efficacy. In the W. pipientis study, we 
established that the temperature range of 15–45°C for the primers and prioritizing 
evenness of binding led to more even amplification of the target genome. In addition, the 
swga-designed sets performed better at selectively amplifying the target than the hand-
designed set in (Leichty & Brisson, 2014). In fact, the Leichty primer set was not 
generated by swga because the maximum distance between primer sites on the Wolbachia 
genome was greater than the specified cutoff. In M. tuberculosis, by starting with a pool 
of primers that bind relatively evenly to the target, we constrained the range of set 
binding evenness by removing primers that cluster on repeat regions. After controlling 
the range of binding evenness at the primer level, the sets with the highest target binding 
density (i.e. lowest mean distance between binding sites) achieved highest coverage, 
suggesting that further refinements of the sets for evenness is not necessary. These sets 
consequently had the lowest ratio of target to background average binding distances. This 
ratio, as a more complete representation of the set’s selectivity than just the binding 
density on the target, had a strongly inverse correlation with the amount of the genome 
covered after sequencing (Figure 3-6). Because both attributes are closely related, it is 
difficult to disentangle the effects of binding density from the effects of a low ratio, and it 
may be that either or both of these attributes contribute to the success of these primer 
sets. Furthermore, some sets had relatively similar ratios (e.g. Mtb7 versus Mtb8), but 
Mtb8 yielded greater genome coverage. This indicates that there are likely other set 
attributes not considered here that also contribute to set efficacy. To compensate for this, 
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we suggest selecting five to ten sets with low ratios to test experimentally, and then 
selecting the best-performing of those sets. 
 
Figure 3-6. Coverage is related to set selectivity. 
The percentage of the Mycobacterium genome covered by each set at ×1 coverage after 50 Mbp of 
sequencing is inversely correlated to the set’s target to background binding distance ratio (e.g. selectivity). 
The smoothed line of best fit (LOESS) is shown by the dotted line. The points and whiskers represent the 
median and standard deviation of the technical replicates. Positive tests are in blue, while negative controls 
are in orange. The random hexamers did not have a definable ratio and are not displayed. 
The swga program does not consider a specific number of primers for each set. Instead, 
swga considers primer sets of different sizes, and reports suggested sets. By exploring a 
range of sizes, the swga program allows the user to find sets with desirable attributes 
without having to guess what the ideal set size will be in advance. 
SWGA is best suited to large scale population genomics studies and may not be cost 
effective in some smaller studies. Developing the SWGA primer set requires up-front 
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costs that need to be recovered in later applications for the method to be cost effective. A 
detailed cost-benefit analysis over multiple applications is presented in Section §3.7.4. 
SWGA is most useful when large numbers of samples are to be sequenced, when the 
target genome is rare in the unamplified sample, and when higher sequencing coverage of 
the target genome is desired. 
Our experiments so far suggest a general workflow that can be used to design primer sets 
for other systems. In particular, we recommend the following guidelines: 
• During swga filter, set the max_gini parameter as low as possible while still yielding 
200 or more primers. 
• For swga find_sets, set the max_sets to 1–5 million to explore a wide range of set 
attributes. 
• Use swga export to export the sets ordered by the distance between binding sites on 
the target (attribute fg_mean_dist). 
• Pick the five to ten sets with lowest fg_mean_dist to test experimentally. Barcode 
each amplicon separately, then pool and sequence with low depth to assess 
performance. Once a high-performing set is identified, sequence that amplicon more 
deeply. This set is now usable in any samples that have similar target/background 
combinations. 
We expect best practices to evolve as SWGA is used more frequently. To facilitate this, 
we have set up a web page on the project’s source repository and a user mailing list. A 
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tutorial on the program’s operation and more extensive documentation on each parameter 
and module is available on the web page as well. 
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3.7. Supplemental Material 
3.7.1. Supplemental Figures 
 
Supp. Figure 3-1. 
The sets identified for Mycobacterium tuberculosis with a mean binding distance on the target less than 5kb 
are shown as a hexplot, where the color intensity represents the number of sets within that range of binding 
density (x-axis) and evenness (y-axis). We used the ‘chull’ function in R to detect the inflection points of 
this distribution. These points (red dots) were the sets that were used for selective amplification. They 
represent various extreme combinations of primer binding evenness and density. Where there were multiple 
points close together, we picked one at random. 
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Supp. Figure 3-2. 
Selective whole-genome amplification increases the proportion of sequencing reads that map to the target 
genome. Direct sequencing of total DNA of 10 flies (column labelled ø) resulted in more than 93% of reads 
mapping to Drosophila while only 4.7% mapped to Wolbachia. By contrast, at least 15% of the reads 
mapped to Wolbachia after select whole genome amplification with the worst performing primer set. All 
primer sets identified by the swga program performed substantially better than primer sets chosen manually 
(Leichty, 2014). Results from each of three replicate SWGA reactions (using 40 ng total DNA per reaction) 
per primer set are shown. The TmL/Even primer set was also run in triplicate with 20 ng total DNA per 
reaction. Results were more similar for replicates within a set than between sets, indicating that SWGA 
performs consistently when using the same primer set. 
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Supp. Figure 3-3. 
The depth of sequencing per 1Gb of sequencing effort (1 Gb * coverage depth / total bp sequenced) is 
shown for all replicates of all primer sets chosen for Wolbachia against Drosophila. Colored lines indicate 
technical replicates, while the black line indicates the unamplified control. The TmL/Even set was re-
sequenced with 20ng of total fly extract DNA in addition to the 40ng used for the other sets. The 
TmL/Even amplicons consistently achieved higher coverage of the Wolbachia genome than the 
unamplified control. 
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Supp. Figure 3-4. 
Variation in the local density of primer binding sites does not account for variation in select whole 
amplification across the Wolbachia genome. The normalized mean sequencing coverage (1 Mb * coverage 
depth / total bp sequenced) across 5 kb windows after amplification is shown relative to the number of 
binding sites within a 20 kb window. Smoothed (LOESS) best fit lines (blue lines) are plotted for each 
technical replicate. Within each primer set, normalized mean coverage did not correlate with the number of 
binding sites in a 20 kb window. However, coverage did vary between primer sets and was generally higher 
for primer sets with a higher number of primer binding sites (Table 1). 
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Supp. Figure 3-5. 
10x coverage of the Mycobacterium genome was limited without additional sequencing effort. Colored 
lines indicate technical replicates, while black dashed lines indicate the unamplified control. 
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Supp. Figure 3-6. 
The depth of sequencing per 1Gb of sequencing effort (1 Gb * coverage depth / total bp sequenced) is 
shown for all replicates of all primer sets chosen for Mycobacterium against the human genome. The first 
four sets yielded higher coverage of the Mtb genome than the unamplified control, as indicated by each the 
colored line for each replicate being higher than the unamplified control (black line). For each set, a density 
histogram of the ratio between the average set coverage and the unamplified control is shown on the right. 
Peaks to the right of the dashed line (indicating a ratio greater than 1) represent overall enrichment. 
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3.7.2. Supplemental Tables 
Supp. Table 3-1. Wolbachia primer sets 
ID Ratio Size Gini Max target dist Mean target dist. 
TmL/Selective 0.0544 9 0.65 3.11E+04 5.33E+03 
TmL/Even 0.1050 7 0.54 3.47E+04 6.85E+03 
TmH/Even 0.0075 2 0.54 1.13E+05 1.31E+04 
TmH/Selective 0.0005 2 0.66 1.28E+05 1.21E+04 
Leichty and Brisson 
2014 0.0163 2 0.71 1.13E+05 5.31E+03 
 
ID 
Target 
dist (sd) 
Mean bg. 
dist Primers 
TmL/Selective 7.00E+03 9.78E+04 
AACATAGATC,AAGAGATACC, AATGTTCGTA, 
ACGTGTTAG, AGAAATTTACTA, 
ATCTAGAGAT, ATCTATGTTAAG, 
TACGTCATAC, TATGCAAGAA 
TmL/Even 7.00E+03 6.53E+04 
AATGTTCGTA, ATAAGCTGAA, TAAAGACATA, 
TACGTCATAC, TATGCAAGAA, TGAGATACC, 
TTTCTGGATC 
TmH/Even 1.55E+04 1.73E+06 CACTGGAATCC, CGCTACTTGTTA 
TmH/Selective 1.80E+04 2.43E+07 CTACGTGTTAGC, CTACTTGTTAGC 
Leichty and Brisson 
2014 1.01E+04 3.25E+05 ATCCAAGTAG, CGGTATCTC  
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Supp. Table 3-2. Mycobacterium primer sets. 
Name ID Ratio Size Gini Max target dist Mean target dist. 
Mtb1 1130935 0.0171 7 0.476 3.27E+04 4.97E+03 
Mtb2 1236643 0.0095 7 0.484 2.75E+04 3.29E+03 
Mtb3 1482488 0.0172 7 0.478 3.77E+04 4.99E+03 
Mtb4 1558358 0.0062 7 0.512 1.49E+04 1.88E+03 
Mtb5 1951361 0.0155 6 0.480 3.44E+04 5.00E+03 
Mtb6 4690256 0.0057 7 0.501 1.50E+04 1.95E+03 
Mtb7 4715948 0.0066 7 0.499 1.39E+04 2.03E+03 
Mtb8 5192056 0.0062 7 0.533 1.87E+04 1.80E+03 
Mtb9 5194179 0.0058 7 0.538 1.87E+04 1.78E+03 
Mtb10 5699436 0.0181 7 0.479 3.12E+04 4.29E+03 
MtbUneven 70336 0.0140 2 0.623 9.21E+04 1.14E+04 
MtbSparse 146196 0.0387 3 0.505 1.00E+05 2.60E+04 
 
Name 
Target 
Dist (sd) 
Mean bg. 
dist Primers 
Mtb1 4.56E+03 2.90E+05 
ACGATCA*A*C,CCGATAT*G*G,CGCGAA*T*A,CGCG
AT*T*A,CGTCGT*A*G,CGTCGT*A*T,TAGTCGA*T*G 
Mtb2 3.12E+03 3.45E+05 
ATTCGT*C*G,CGCGAA*T*A,CGGTAT*C*G,CGTCGT*
A*A,CGTCGT*A*T,GATTGTC*G*A,TACGAA*C*G 
Mtb3 4.69E+03 2.90E+05 
ATCGGAT*T*C,CGATAC*G*T,CGCGAT*A*A,CTACGA
*C*G,CTCGATA*C*C,GATCGAC*T*C,TCGATCA*A*C 
Mtb4 1.92E+03 3.04E+05 
ATCGACA*A*C,CGAATC*C*G,CGTTAC*G*G,CTACG
A*C*G,GACGAT*C*G,GATCGAC*T*C,TCGACG*A*A 
Mtb5 4.71E+03 3.22E+05 
ATATCGG*T*G,CCGAAT*C*G,CGGTTA*C*G,GACGA
CT*A*C,GATGATC*G*A,TGGATAT*C*G 
Mtb6 1.95E+03 3.41E+05 
CCGAAT*C*G,CGCGAA*T*A,CGCTAT*C*G,CGGTAT*
C*G,CGGTTA*C*G,CGTCTA*C*G,TCGACG*A*A 
Mtb7 1.99E+03 3.09E+05 
ATCGACA*A*G,CCGAAT*C*G,CGCGAA*T*A,CGCTA
T*C*G,CGGTAT*C*G,CGTCTA*C*G,TCGACG*A*A 
Mtb8 1.96E+03 2.92E+05 
ACGATCA*A*C,CGAATC*C*G,CGACGA*A*A,CGACG
A*T*A,CGATAC*C*G,TACGAC*G*A,TCGACG*A*A 
Mtb9 1.96E+03 3.05E+05 
CGAATC*C*G,CGACGA*A*A,CGACGA*T*A,CGATAA
*C*G,CGATAC*C*G,TACGAC*G*A,TCGACG*A*A 
Mtb10 4.09E+03 2.37E+05 
CGAAAC*G*A,CGATATC*C*A,CGATTC*G*G,CGGTA
TT*G*A,CGTAGT*C*G,CGTTAC*G*T,TGTAGTC*G*A 
MtbUneven 1.45E+04 8.10E+05 CGATATT*G*C,CGTTAC*C*G 
MtbSparse 2.48E+04 6.71E+05 CGTTCG*T*A,TGATATC*G*C,TTCGACT*A*C 
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3.7.3. Supplemental Data 
3.7.3.1. Swga settings for Wolbachia pipientis against Drosophila melanogaster 
 
[count] 
min_size = 5 
max_size = 12 
min_fg_bind = 20 
max_bg_bind = 10000 
max_dimer_bp = 4 
exclude_threshold = 1 
 
[summary] 
bg_length = 145523498 
fg_length = 1285894 
 
[filter] 
max_primers = 200 
bg_length = 145523498 
fg_length = 1285894 
min_fg_bind = 41 
max_bg_bind = 474 
min_tm = 15 
max_tm = 45 
 
[find_sets] 
min_size = 2 
max_size = 12 
max_dimer_bp = 4 
min_bg_bind_dist = 30000 
bg_genome_len = 145523498 
max_fg_bind_dist = 36000 
max_sets = 1 
workers = 3 
 
[score] 
bg_genome_len = 145523498 
score_expression = (fg_dist_mean * fg_dist_gini) / (bg_dist_mean) 
 
[export] 
window_size = 10000 
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3.7.3.2. Swga settings for Mycobacterium tuberculosis against Homo sapiens. 
 
[count] 
min_size = 5 
max_size = 12 
min_fg_bind = 44 
max_bg_bind = 21770 
max_dimer_bp = 3 
exclude_threshold = 1 
 
[export] 
window_size = 10000 
 
[filter] 
max_primers = 200 
min_fg_bind = 50 
max_bg_bind = 21770 
min_tm = 15 
max_tm = 45 
max_gini = 0.6 
 
[find_sets] 
min_size = 2 
max_size = 7 
max_dimer_bp = 3 
min_bg_bind_dist = 60000 
max_fg_bind_dist = 100000 
max_sets = -1 
workers = 4 
score_expression = (fg_dist_mean * fg_dist_gini) / (bg_dist_mean) 
 
[score] 
score_expression = (fg_dist_mean * fg_dist_gini) / (bg_dist_mean) 
 
3.7.3.3. Code used in this project 
For code used in analysis and figures, please refer to 
https://github.com/eclarke/swga_paper 
3.7.4. Cost analysis for SWGA 
The SWGA method improves the efficiency of genomic sequencing when targeting the 
genome of a specific organism in the presence of contaminating DNA. However, 
implementing SWGA itself incurs costs, and so not all applications will benefit from its 
use. In particular, SWGA is generally more cost effective studies that require sequencing 
a large fraction of the target genome from multiple samples. For experiments 
necessitating new primer design, as described in this study, either the depth of sequencing 
coverage or number of samples must be large enough to offset initial cost of purchasing 
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and testing primer sets. For these reasons, SWGA, using newly designed primer sets, is 
not necessarily cost effective for applications with very small target genomes, low 
coverage depth , or small numbers of samples. 
Here we present a cost analysis, including the cost of de novo primer set design and 
testing. To highlight the areas where SWGA is most cost effective, we have performed 
this analysis across range of sequencing depths for three target organisms: 
Mycobacterium tuberculosis in humans, Plasmodium vivax in humans, and Wolbachia 
pipientis in fruit flies. The cost of implementing and performing SWGA is compared 
directly to achieving the same depth and coverage of sequencing by direct sequencing of 
the sample without SWGA amplification. 
For each target, we compare the cost of SWGA sequencing for a given number of 
samples, including primer set design and testing, to that of sequencing directly from the 
starting DNA mixture. We calculate the cost of sequencing samples at 1X and 10X 
coverage and with the goal of covering 50%, 75%, and 80% of the target genome, thus 
illustrating how the cost effectiveness of SWGA varies with depth and breadth of 
sequencing. 
The following is a breakdown of the costs associated with sequencing and the SWGA 
process. All costs are in US dollars, and reagent prices are accurate as of the time of 
writing (Feb 2017). 
Supp. Table 3-3. One-time costs associated with SWGA. 
Step Unit Cost 
Primer design Computation time* $5.88 
Primer testing Miseq (reagents + sequencing) $1,500.00 
 
Computation time measured as the cost of running swga on the Penn High Performance Computing cluster 
on one node for one week at $0.035/hr/node. 
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Supp. Table 3-4. Per-sample costs associated with SWGA. 
Step Unit Cost/sample 
Primer Set (average for 10 primers) Primer oligos $0.02 
SWGA Reaction Phi29 + Buffer $5.70 
SWGA Reaction DNTPs $0.41 
Sequencing (Nextera - Hiseq) Kit reagents $65.00 
Cost per base on an Illumina Hiseq using Nextera: $0.000000094. 
 
Total cost is $71.13/sample. Costs per sample were estimated from the cost of and number of uses yielded 
by the reagent (for specific reagent catalog numbers, see the main text). 
To calculate the cost of sequencing some number of samples 𝑛 with SWGA, we added 
the fixed costs (𝐶𝑓) and multiplied the variable costs 𝐶𝑣 by the number of samples. We 
then empirically determined the number of bases required to achieve the required depth 
of coverage (𝑁𝑏𝑝, see Table 2 at end of document). This was multiplied by the above cost 
per base (𝐶𝑏𝑝)and the number of samples: 
CostSWGA(𝑛) = 𝐶𝑓 + (𝐶𝑣 × 𝑛) + (𝑁𝑏𝑝 × 𝐶𝑏𝑝 × 𝑛) 
The cost of directly sequencing a sample (without SWGA) is the cost of the sequencing 
reagents (𝐶𝑟) and the sequencing itself: 
CostUnamplified(𝑛) = (𝐶𝑟 × 𝑛) + (𝑁𝑏𝑝 × 𝐶𝑏𝑝 × 𝑛) 
In each plot, the intersection point between the two lines (SWGA vs unamplified) 
represents the point at which the SWGA method becomes more cost efficient. This is 
heavily influenced by the relative efficiency gains yielded by SWGA, which itself is a 
function of the target and host genomes. For some applications, like sequencing W. 
pipientis at low coverage depth and breadth, SWGA is not cheaper than conventional 
sequencing. 
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Ex. 2: M. tuberculosis at 10X depth o ver 75% of the genome
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Ex. 3: M. tuberculosis at 10X depth o ver 50% of the genome
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Ex. 4: M. tuberculosis at 1X depth o ver 80% of the genome
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Ex. 5: M. tuberculosis at 1X depth o ver 75% of the genome
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Ex. 6: M. tuberculosis at 1X depth o ver 50% of the genome
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Ex. 7: P. vivax at 10X depth over 80% of the genome
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Ex. 8: P. vivax at 10X depth over 75% of the genome
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Ex. 9: P. vivax at 10X depth over 50% of the genome
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Ex. 10: P. vivax at 1X depth over 80% of the genome
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Ex. 11: P. vivax at 1X depth over 75% of the genome
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Ex. 12: P. vivax at 1X depth over 50% of the genome
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Ex. 13: W. pipientis at 10X depth over 80% of the genome
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Ex. 14: W. pipientis at 10X depth over 75% of the genome
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Ex. 15: W. pipientis at 10X depth over 50% of the genome
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Ex. 16: W. pipientis at 1X depth over 80% of the genome
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Ex. 17: W. pipientis at 1X depth over 75% of the genome
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Ex. 18: W. pipientis at 1X depth over 50% of the genome
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Supp. Table 3-5. Sequencing required to achieve desired coverage. 
Example Organism Depth Coverage SWGA (bp) Unamplified (bp) 
1 M. tuberculosis 10 80 3,091,559,998 5,527,190,382 
2 M. tuberculosis 10 75 2,520,410,974 5,262,496,048 
3 M. tuberculosis 10 50 1,223,345,194 4,267,942,796 
4 M. tuberculosis 1 80 303,869,124 710,912,333 
5 M. tuberculosis 1 75 238,173,500 612,325,622 
6 M. tuberculosis 1 50 85,299,735 307,065,400 
7 P. vivax 10 80 4,129,854,209 40,750,765,958 
8 P. vivax 10 75 2,780,236,529 38,803,668,507 
9 P. vivax 10 50 837,785,449 31,291,283,092 
10 P. vivax 1 80 590,545,217 5,210,647,250 
11 P. vivax 1 75 289,985,276 4,493,713,988 
12 P. vivax 1 50 64,803,452 2,249,610,375 
13 W. pipientis 10 80 71,621,179 441,055,975 
14 W. pipientis 10 75 62,712,293 390,478,303 
15 W. pipientis 10 50 36,527,254 256,900,749 
16 W. pipientis 1 80 7,234,721 50,185,804 
17 W. pipientis 1 75 5,946,277 42,309,224 
18 W. pipientis 1 50 2,451,818 19,419,362 
3.7.4.1. Conclusions 
As shown in Examples 1-3 and 7-12, the cost effectiveness of SWGA is more significant 
when pursuing higher coverage depth across the target genome. In M. tuberculosis, 
SWGA becomes more cost effective when considering sequencing more than 8 samples. 
In P. vivax SWGA is nearly always more cost effective, representative of the variable 
effect the target and host genomes can play on the final efficiency gains. 
For low-depth sequencing, and for small genomes such as W. pipientis, the benefit is only 
realized at higher numbers of samples. Low-depth sequencing of M. tuberculosis is only 
more cost-effective with SWGA when more than 65 samples are being sequenced (Ex 4-
6). Again indicative of the variable influence of the target genome size, however, low-
depth coverage of P. vivax is more cost-effective with SWGA by only 5 or so samples. 
As a contrast, it is unlikely that SWGA would be cost-effective at all for low-depth 
sequencing of W. pipientis given that the lines in Examples 16-18 will only converge 
after a very large (>10,000) number of samples. Importantly, these graphs include the 
cost of designing and testing new SWGA primers. In situations where primer sets already 
exist, SWGA would become cost-effective at even lower numbers of samples. 
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These graphs show that for a variety of target/host genomes, SWGA's benefits are 
greatest when 1) large numbers of samples are studied, 2) when high depths of coverage 
are needed, and 3) a large proportion of the genome should be covered. 
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Chapter 4. T cell dynamics and response of the microbiota 
after SCID-X1 gene therapy 
This chapter is based upon work by Erik Clarke1, Frances Male, Andrew 
Connell1, Nadia Kadry1, Arwa Abbas1, Young Hwang1, John Everett1, Casey 
Hofstaedter, Judith Kelsen, Marina Cavazzana, Emmanuelle Six, Alain Fischer, 
Luigi Notarangelo, Salima Hacein-Bey Abina, Don Kohn, David Williams, Sung-
Yun Pai, and Frederic D. Bushman1. 
1. Dept. of Microbiology, University of Pennsylvania School of 
Medicine 
4.1. Abstract 
Mutation of the IL2RG gene results in a severe combined immune deficiency (SCID-X1) 
that has been treated successfully with hematopoietic stem cell (HSC) gene therapy.  
SCID-X1 gene therapy results in reconstitution of the previously lacking T-cell 
compartment, allowing analysis of the roles of T-cells in humans by comparing before 
and after gene correction.  Here we interrogate T-cell reconstitution using four forms of 
high content analysis.  1)  Estimation of the numbers of transduced progenitor cells by 
monitoring unique positions of integration of the therapeutic gene transfer vector.  2)  
Estimation of T-cell population structure by sequencing of the TCR-beta VDJ-
recombination products.  3)  Metagenomic analysis of microbial populations in 
oropharyngyl, nasopharyngal and gut samples.  4) Metagenomic analysis of viral 
populations in gut samples.  Comparison of progenitor and T-cell populations allows 
estimation of a minimum number of cell divisions needed to generate the observed 
populations.  Analysis of microbial populations shows the effects of immune 
reconstitution, including normalization of gut microbiota and clearance of viral 
infections. Metagenomic analysis revealed a notable enrichment of genes for antibiotic 
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resistance in gene-corrected subjects relative to healthy controls.  These data highlight the 
novel analytical avenues made possible by successful SCID-X1 gene therapy. 
4.2. Introduction 
Several primary immunodeficiencies have now been treated successfully by gene-
correction of hematopoetic stem cells (HSC) with integrating vectors (Aiuti et al., 2013; 
Aiuti et al., 2007; Aiuti et al., 2002; Biffi et al., 2013; Marina Cavazzana-Calvo, Andre-
Schmutz, & Fischer, 2013; Gaspar et al., 2011; Gaspar et al., 2004; Hacein-Bey-Abina et 
al., 2010; Hacein-Bey-Abina et al., 2002).  This work has benefited many patients, and in 
addition provides a unique window on immune mechanisms.  In SCID-X1, the first 
primary immunodeficiency treated successfully by gene transfer, patients harbor 
mutations in the IL2RG gene, which encodes the common gamma chain, a component of 
several cytokine receptors important in T and NK-cell growth and development(Kovanen 
& Leonard, 2004; Noguchi et al., 1993; Puck et al., 1993).  Patients typically lack these 
cells before correction(Kennedy et al., 2000; Lodolce et al., 1998; Puel, Ziegler, Buckley, 
& Leonard, 1998), but afterwards show robust T reconstitution and transient NK-cell 
reconstitution, accompanied by restoration of considerable immune function (Gaspar et 
al., 2011; Gaspar et al., 2004; Hacein-Bey-Abina et al., 2010; Hacein-Bey-Abina et al., 
2002).  Gene correction thus provides a unique opportunity to study the onset of T cell 
function in previously deficient human subjects. 
In the first gene therapy trial to treat SCID-X1, early designs of gammaretroviral vectors 
were used (Gaspar et al., 2011; Gaspar et al., 2004; Hacein-Bey-Abina et al., 2010; 
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Hacein-Bey-Abina et al., 2002), which were the only vector type available at the time.  
These vectors contain strong enhancers derived from the starting retroviral backbone.  
The enhancers supported efficient expression of the corrective IL2RG gene and allowed 
successful gene correction.  However, subsequent experience implicated these vectors in 
insertional mutagenesis, in which vector signals activated transcription of host proto-
oncogenes, in some cases associated with severe adverse events(Hacein-Bey-Abina, von 
Kalle, Schmidt, Le Deist, et al., 2003; Howe et al., 2008).   
A second trial was carried out to treat SCID-X1 using an improved vector in which the 
strong enhancer sequences were deleted (Hacein-Bey-Abina et al., 2014), and a more 
specific promoter was used to express the therapeutic IL2RG  gene copy.  T-cell numbers 
after correction were indistinguishable in the first and second trials.  So far, no severe 
adverse events have been linked to insertional activation in the second trial.   
In this study, we used multiple high throughput sequence-based methods to analyze 
samples from the SCID-X1 trials, with the goal of probing immune mechanisms and the 
resulting effects on microbial communities.  To assess the number and distributions of 
gene-corrected precursor cells producing T-cells, deep sequencing of sites of vector 
integration was used (C. Berry, Hannenhalli, Leipzig, & Bushman, 2006; C. C. Berry et 
al., 2012; C. C. Berry et al., 2017; Hacein-Bey-Abina et al., 2014; Hacein-Bey-Abina, 
von Kalle, Schmidt, Le Deist, et al., 2003; Hacein-Bey-Abina, Von Kalle, Schmidt, 
McCormack, et al., 2003; Howe et al., 2008; Mitchell et al., 2004; Schroder et al., 2002; 
Sherman et al., 2017; G. P. Wang et al., 2010; G. P. Wang et al., 2007), where each 
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unique integration site marked a distinct T-cell progenitor. T-cell development could be 
followed at a later step by using DNA sequencing to track rearrangements of gene 
segments encoding the T-cell receptor-beta CDR3 region (Boyd et al., 2009; 
Campregher, Srivastava, Deeg, Robins, & Warren, 2010; H. S. Robins et al., 2009; H. S. 
Robins et al., 2010; Weinstein, Jiang, White, Fisher, & Quake, 2009).  Immune cells 
contribute to control of the resident microbiota, so the consequences of T-cell 
reconstitution were assessed by deep sequencing of oral, fecal and nares samples to 
characterize the full microbiota using shotgun metagenomics.  In a separate analysis, 
samples were enriched biochemically for viral particles, RNA and DNA extracted, and 
then the viral content monitored in fecal samples.  
The data support a wealth of new inferences on T-cell growth and immune activity after 
reconstitution.  For example, a minimum estimate for the numbers of cell divisions 
between progenitor cells and mature T-cells was developed by comparing population 
sizes from integration site and TCR sequence data.  In the microbiome data, 
normalization of microbial communities was documented following successful treatment 
in several subjects.  Viral infections, several not detected clinically, could be shown to be 
widespread but often cleared with immune reconstitution.  TCR diversity could be 
compared for selected samples from the SCID1 and SCID2 trails, providing information 
on the durability of reconstitution and effects of adverse events on TCR diversity.  Thus 
these data begin to outline the utility of “multi-omics” analysis of gene correction in 
primary immunodeficiency. 
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4.3. Results 
4.3.1. Experimental strategy 
Our comparative analysis of gene-corrected progenitors and daughter T cells focused on 
four patients from the SCID-2 trail (Hacein-Bey-Abina et al., 2014 ) and three patients 
from the SCID-1 trial (Hacein-Bey-Abina et al., 2010) for whom samples were available 
Figure 4-1.  Patient characteristics are summarized in Supp. Table 4-1.  Additional 
subjects were studied for which we did not have T cell samples, but did have peripheral 
blood mononuclear cell samples (PBMC, Supp. Figure 2-1). Adverse events took place in 
the SCID-1 trial involving subjects F107 and F110 at times 68 months and 33 months 
after infusion (Hacein-Bey-Abina et al., 2010; Hacein-Bey-Abina et al., 2014; G. P. 
Wang et al., 2010). The time points analyzed here are well after these adverse events, 
allowing assessment of the effects of leukemia and chemotherapy on progenitor cell and 
T cell populations.  One subject in the SCID2 trial, B205, was transplanted twice without 
achieving clinical reconstitution.  Samples from the two unsuccessful treatments are 
designated B205 and B205b. 
 Vector integration sites and the T cell repertoire were monitored through regular per-
protocol blood draws, followed by isolation of CD3+ populations. Sorted cells were 
subject to DNA extraction and then amplification of either integration sites (mostly 
previously reported in (Hacein-Bey-Abina et al., 2010; Hacein-Bey-Abina et al., 2014; G. 
P. Wang et al., 2010); Supplementary Table X) or mature TCR beta loci (Supp. Table 
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4-3; data new here), followed by sequencing. Vector integration sites mark progenitor 
cells capable of delivering mature T-cells to the periphery.  Rearranged TCR beta loci 
mark mature T-cells present in blood. Time points from the integration site analysis were 
chosen to match those used in the TCR analysis—characterization of additional time 
points for integration site distributions in SCID-X1 gene therapy can be found in (M. 
Cavazzana-Calvo et al., 2000; Hacein-Bey-Abina et al., 2010; Hacein-Bey-Abina et al., 
2014; Howe et al., 2008; Thrasher et al., 2006; G. P. Wang et al., 2010; G. P. Wang et al., 
2008). 
Microbiome samples were available for six SCID-2 patients (B201, B203, B204, B205, 
B207, and F201). Oral, nasal, and gut microbiota were sampled via collection of 
oropharyngeal swabs, nasopharyngeal swabs, and stool samples. Sampling times ranged 
from 4 to 181 months post infusion of corrected cells. Sample acquisition was at times 
limited by clinical and practical considerations.  
As controls, we analyzed TCR-beta sequences from CD3+ cells from five healthy 
children and three healthy adults.  Healthy subject demographics are in Supp. Table 4-1. 
Cross-sectional microbiome samples were collected from the same subjects and analyzed 
as for the SCID gene-corrected samples.  
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Figure 4-1. 
Sampling schedule for eight SCID-X1 gene-corrected subjects studied for integration site distributions and 
TCRB CDR3 sequence composition. A)  Times of sample acquisition after cell infusion. B) Population 
sizes of inferred progenitor cells deduced from marking with unique sites of vector integration. Integration 
site data is in Supplementary Table X, and summaries of genes near sites of vector integration are in 
Supplementary Figure 2. The x-axis shows the time since cell infusion.  The y-axis shows the population 
size reconstructed using Chao1 from the numbers of unique integration sites and replicate sampling. 
Samples are named for the site of gene correction (B indicates Boston, F indicates France; the next digit 
indicates the trail 1=SCID1, 2=SCID2, and the next two digits indicate the patient number within that trial). 
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4.3.2. Integration site analysis 
To characterize progenitor cells delivering T-cells to the periphery, we determined the 
sites of vector integration in patient chromosomes (31 total samples). Because of the 
large size of the human genome, each integration site uniquely marks the descendants of 
a single gene-corrected progenitor. Summaries of genes near integration sites in the most 
expanded clones at each time point are in Supp. Figure 4-2.  The numbers of integration 
sites detected in purified T cell samples ranged widely, from as few as 62 to as many as 
2009.  Reconstruction of population sizes using the Chao1 estimator suggested minimal 
sizes of 144 to 6018 active progenitors.  
For the SCID2 subjects, we found that the estimated total number of vector integration 
sites was relatively constant over the time intervals analyzed (Figure 4-1B), in the range 
of ~1000 predominant clones yielding circulating cells (Supp. Table 4-2).  Numbers 
varied by subject, with subject B203 showing consistently higher levels, while B205, a 
case of unsuccessful reconstitution, showing consistently lower levels. 
For the SCID1 subjects, numbers of unique sites identified varied from 263 to 682; 
reconstructed minimal population sizes ranged from 628 to 1287.  Comparison of mean 
values shows no difference in the numbers of unique integration sites in SCID2 subjects 
compared to SCID1 subjects (p=0.17).  
Population sizes of progenitors were compared between SCID1 subjects who suffered 
adverse events (F107, F110) versus those who did not (F102, F106), or versus SCID2 
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subjects.  Treating time points as independent tests, no systematic differences were 
detected comparing within SCID1 subjects; a marginal difference was detected with a 
comparison of adverse events versus no adverse events (adverse event samples compared 
to pooled SCID1 and 2; p=0.041).   
4.3.3. TCR-beta CDR3 analysis 
Clonal structure of T-cell populations was investigated by analyzing TCR-beta 
rearrangements in genomic DNA from blood CD3+ cells (Figure 2).  CDR3 region 
sequences were conceptually translated, and numbers of productive rearrangements 
quantified (Figure 4-2A).  For healthy adults, numbers ranged from 18,000 to 27,000 per 
sample.  For healthy children, numbers ranged from 18,000 to 22,000 per sample.  For 
SCID2, most samples were close to this range (12,000 to 33,000 per sample; no 
significant difference in medians).  For SCID1, results were slightly lower, with four out 
of five samples between 15,000 and 23,000.  The exceptional sample was from subject 
F107, who suffered an adverse event and was treated by chemotherapy—in this case the 
number was only 5,000 unique CDR3 sequences.   
For all the CDR3 samples sequenced, the numbers of CDR3 clonotypes in the subject 
were much larger than the numbers sequenced, so we used Chao 2 and replicate sampling 
to estimate the number of CDR3 variants present.  Estimators are sensitive to sampling 
effort, so our estimates represent minimal values.  Focusing on samples analyzed over 
multiple replicates, we estimate population sizes of 26,000 to 2,600,000 CDR3 variants. 
The median for SCID2 samples was not different from that of healthy children, but the 
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median for SCID1 was significantly lower than for the healthy children (p=0.026; 
Wilcoxon rank sum test). 
Analysis of trends over time suggested that each subjects’ repertoire was becoming more 
diverse (Figure 4-2B).  The one exception was the unsuccessful case of reconstitution 
(B205), which did not show longitudinal increase.  Inferred CDR3 population sizes in 
gene-corrected subjects approached or equaled sizes in healthy children, and exceeded 
those in healthy adults. 
To begin to characterize repertoire composition, we used Bray-Curtis dissimilarity and t-
SNE to cluster samples (Figure 4-2C).  Replicates from each subject closely resembled 
those from the same subject at different time points, but differed from other subjects.  No 
systematic differences were observed comparing SCID 1 and SCID2, or comparing either 
data set to healthy controls. 
Recombination involving the most frequently used V (Figure 4-2D) and J (Figure 4-2E) 
gene segments was next quantified and compared. Usage of gene segments was 
quantified for healthy children and averaged, then the profile was compared to gene-
corrected SCID subjects.  The great majority of gene-corrected samples did not show 
significant differences from the distribution in healthy children, both in the analysis of V 
and J gene segment usage.  The only exception was V gene usage in SCID2 subject 
B201, where particularly early time point samples were available (6 and 12 months after 
infusion of corrected cells). This subject was successfully corrected, so the unusual 
distribution is not indicative of clinical failure.  We speculate that at the very early time 
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after gene correction newly produced T-cells are only beginning to be subjected to the 
homeostatic mechanisms that yield the consistent mature repertoire.  Figure 2F shows the 
usage of V-J pairs within subjects, emphasizing the occasional outgrowth of expanded 
clones, potentially in response to antigen, followed by down-modulation of abundance. 
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Figure 4-2. 
Analysis of TCRB CDR3 sequences. A) The unique numbers of rearranged genes detected are shown.  The 
colors indicate in frame rearrangements (blue), frameshifts (tan) and stop codons (red).  B) Richness and 
evenness of the inferred TCRB CDR3 populations.  Patients are color coded as indicated on the right.  The 
ranges of healthy adults and children are shown by the grey and salmon shading, respectively. C) 
Clustering of the samples sequenced using Bray-Curtis similarity and t-SNE.  The association of patients 
with samples is shown by the key at the right. D)  V gene usage. The patient of origin is marked at the top 
of each panel.  E) J gene usage. F) Heat map summarizing the frequencies of utilization of the most 
common V and J pairs. Subjects studied are marked at the top. Time of sampling is shown on the right. 
4.3.4. Tracking T-cell ontogeny 
Comparison of the estimated lower bound for the number of unique integration sites per 
sample with the lower bound for the number of unique TCR sequences allows estimation 
of a lower bound on the number of cell divisions required to generate the TCR-beta cell 
population from gene-corrected precursors (Figure 4-3. We calculated the minimum 
number of cell divisions as the base-2 logarithm of the difference between the estimated 
population size of unique T cells and the estimated population size of integration sites:  
CellDivisions = log2(TCRs −  IntSites) 
We found a relatively consistent range of minimum cell division values across patients 
and timepoints, with a median of 8.41 and a minimum and maximum of 5.97 and 17.45. 
Considering only the patients with successful, non-repeated therapy (B201, B203, and 
B207), the range was tighter, with a median of 8.41 and a minimum and maximum of 
5.97 and 14.72, respectively.  The fraction of progenitor cells that die in the thymus is 
unknown, so our estimates are lower bounds for the required number of cell divisions.  
The highest values were for subject B205, for whom reconstitution was unsuccessful.  
We speculate that homeostatic mechanisms may have resulted in signaling to a limited 
number of progenitors to divide with increased frequency in this subject. 
 122 
 
 
Figure 4-3. 
Minimum numbers of cell divisions between progenitors and daughter T cells.  The x-axis shows time after 
corrected cell infusion.  The y-axis shows the estimated number of cell divisions calculated as described in 
the text.  The subjects studied are indicated beneath the figure as indicated by the color code. 
4.3.5. Response of the microbiome to reconstitution 
Microbiota community structure was analyzed for six gene-corrected subjects (Figure 
4-4A) by extraction of DNA from swabs (oral and nasal samples) or stool (fecal samples) 
followed by shotgun metagenomic sequencing.  Numbers of samples available per 
subject ranged from one to seven.  The numbers of sequences acquired per sample 
averaged 3,625,000 (oral), 72,000 (nasal) and 8,746,000 (fecal).  Sequencing reads were 
quality filtered as described in Methods and then assigned to microbial taxa using Kraken 
(Wood & Salzberg, 2014) .  
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The analysis of gut microbiota (Figure 4-4B) emphasized the differences between gut 
microbiota of healthy children (left four columns) versus SCID gene-corrected subjects.  
The healthy subjects were colonized predominantly with Bacteriodes, which is typical of 
healthy gut, whereas the SCID-subjects showed a range of major colonists.  B201 was 
colonized mainly with Bifidobacteria, which is characteristic of healthy breast-fed babies 
(Pannaraj et al., 2017). However, subjects B203 and B205 (early times) were colonized 
with Veillonella, which is typically an oral bacteria, possibly indicative of colonization 
with this organism along the length of the GI tract. Subject B204 showed high level 
colonization with Enterobacteriaceae, typical of dysbiotic states.  Early samples from 
subjects B207 and F201 were dominated by viruses, even though whole stool was 
sequenced, with infection by adenovirus and bocavirus respectively. 
Oral samples from the healthy controls were dominated by typical oral bacteria, including 
Prevotella, Streptococcus, Neisseria, and Haemophilus.  In contrast, B203 at the earliest 
time point was dominated by Bocavirus, B204 and B205 showed high level domination 
by Streptococcus, and B207 was dominated by Rothia. 
In nasopharyngeal samples, healthy subjects were dominated by Moraxella, 
Staphylococcus and Propionibacterium.  SCID subjects contained these lineages to 
varying degrees, but also showed high level colonization by Streptococcus, 
Corynebacterium, and others. 
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Figure 4-4. 
Longitudinal analysis of the microbiome during SCID-X1 gene correction. A) Timing of sample 
acquisition.  B) Longitudinal analysis of the nasopharyngeal microbiome.  Each column indicates a sample.  
Samples are grouped by subject as indicated at the top.  Each row summarizes the proportions of a specific 
microbial taxa inferred using Kraken.  Abundance is color coded as indicated to the right. C) As in B, but 
stool samples.  D) As in B, but oropharyngeal samples. 
We compared the full microbial compositions of the samples using Bray-Curtis 
dissimilarities and found that the three sample types clustered by body site of origin 
(Figure 4-5A, PERMANOVA p-value < 0.001). We also found that each subject 
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clustered with themselves throughout all timepoints, reflecting consistently higher inter-
subject variability than intra-subject variability (PERMANOVA p-value < 0.001). In 
several patients (B201, B205, and B207), the microbial communities began resembling 
healthy children more at late times after cell infusion (Figure 4-5B), potentially reflecting 
a combination of improving immune function and reduction in antibiotic usage. 
Analysis of taxonomic richness provides insight into microbial community health, since 
low richness is often associated with abnormal outgrowth of opportunistic organisms.  
For stool, richness increased for 4/6 subjects over time, potentially indicative of 
improving gut health (Figure 4-5C). Unexpectedly, of the four subjects for whom oral 
samples were available, all showed abnormally low richness at every time point.  For 
many this was associated with particularly high Streptococcus colonization, an 
observation that might be of interest to investigate further for possible clinical 
implications.  Nasopharyngeal microbiota showed richness comparable to healthy 
controls.   
SCID patients were treated with a wide variety of antibiotics before and after therapy to 
mitigate opportunistic infections. To assess whether this was associated with an increase 
in antibiotic resistance gene representation, we quantified antibiotic resistance genes in 
the stool sequence samples using ShortBRED and the CARD antibiotic resistant factor 
database (Figure 4-5D). We saw an increase in the total quantity of antibiotic resistance 
genes. The SCID patients had a higher level of antibiotic resistance genes in their stool 
than healthy subjects (pooled across timepoints, p = 0.048). These results indicate that the 
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antibiotic regimen increases both general levels of antibiotic resistance genes. For patient 
B201, who had a timepoint 24 months after therapy, the level of antibiotic resistance 
genes decreased substantially between the 5 month and 24 month timepoint. At this 
timepoint, the patient was no longer on any medications, which suggests that antibiotic 
resistance gene load may decrease after treatment ceases.  
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Figure 4-5. 
Microbiome community analysis. A) Sample clustering using Bray-Curtis dissimilarity. Different sample 
types are marked by the colors, healthy versus SCID are shown by the shapes. B) Comparison of stool 
samples for each patient queried to healthy controls.  Samples were clustered using Bray-Curtis 
dissimilarity. Each panel compares one SCID subject samples (indicated at the top) to healthy control 
samples (shown in grey). Elapsed time is shown using the color code (bottom). C)  Representation of 
selected antibiotic resistance genes in the three sample types studied.  Each column indicates a 
metagenomic data set from the subject listed at the top.  Each row summarizes the abundance of an 
antibiotic resistance gene class.  The tiles are colored by reads per kilobase of target per million sequences 
reads (RPKM); the color code is to the right of the panel. 
4.3.6. Response of the virome 
Viral particles were partially purified from stool, the DNA and RNA purified and 
sequenced.  Reads were assigned using Kraken, then extensive filtering was carried out to 
remove contaminants and artifacts.  Figure 4-6 shows the resulting attributions. For RNA 
viruses, high level colonization was detected with astrovirus (B204 and B205) and 
sapovirus (B203).  For DNA viruses, numerous bacteriophage lineages were seen.  For 
viruses infecting animal cells, high levels of infection were seen for adenovirus in B201, 
bocavirus in B203, and betatorquetenovirus (anellovirus) in B205.  The adenovirus and 
bocavirus infections diminished over time after successful gene correction.  
Betatorquetenovirus is a normal commensal, and persisted. 
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Figure 4-6. 
Virome analysis. A) Heat map summarizing RNA viruses detected. Each column indicates a sample from 
the patient indicated at the top of the heatmap, each row indicates a type of virus.  The tiles are colored 
according to proportion of total viral reads. B) Heat map summarizing DNA viruses detected. Markings as 
in A. 
4.4. Discussion 
We present here a first look at the co-development of the microbiome and immune 
system in patients after gene therapy for SCID. We used targeted sequencing of vector 
integration sites to model the number of gene-corrected progenitor cells, and TCR 
sequencing to capture the development of the T cell repertoire following therapy. The 
combination of these data allowed a lower-bound approximation of the number of cell 
divisions required to progress from a lymphopoetic stem cell to a circulating T cell, a 
measurement uniquely possible thanks to gene marking by integration. We used shotgun 
metagenomic sequencing in longitudinal samples to track early-term changes in the gut, 
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oral and nasopharyngeal microbiome coincident with therapy. In a subset of these 
timepoints, we purified and sequenced RNA and DNA viruses to show clearance of 
pathogenic viruses with immune reconstitution and, in some patients, the presence of 
viruses not reported in clinical records.  
This estimate of cell divisions is limited by wide confidence intervals in the estimators 
for unique TCRs and integration site population sizes, but despite that most of the 
timepoints indicated roughly nine cell divisions between the progenitor stem cell and a 
circulating T cell. This is a minimum value because the amount of cell death during T-
cell ontogeny is unknown and likely high. This helps specify the functional capacity of 
the lymphoid precursor cell targeted in initial transduction.  
The microbiome analysis provided new evidence on how SCID gene therapy patients 
progress to healthier phenotypes after successful therapy. Their immune cell diversity, as 
measured by TCR sequencing, consistently moved from the oligoclonal range of older 
adults and into a higher diversity range more characteristic of healthy children of that 
age. Further, their overall circulating T cell richness showed a similar movement towards 
a healthy and age-typical state. This is concordant with the observed results of healthy 
immune function in these patients and shows that sequencing metrics of the T cell 
repertoire correlate with clinical outcomes. 
As in their immune repertoires, the microbiota of these patients changed in ways that 
resembled the microbiomes of healthy children. We saw an increase in diversity and 
richness of the microbes in the gut and oro- and nasopharygeal compartments and the 
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outgrowth of bacteria associated with healthy gut function. In some patients, we were 
also able to detect bacteria that may be associated with negative outcomes and antibiotic 
resistance, potentially as a result of extended exposure to antibiotics and hospitalization. 
An unexpected finding was the consistently low diversity of SCID oral samples, and the 
high colonization with Streptococcus.  It will be of interest to assess whether this is seen 
in other immunodeficient subjects, and target investigations of possible oral pathology 
associated with this organism. 
In some of these patients, we found viruses known to cause enteropathic conditions in 
humans, including astrovirus, bocavirus and adenovirus. In the case of patient B207, the 
adenovirus detection was clinically corroborated with a diagnosis of adenoviremia. In 
both, the viruses were cleared in later timepoints, likely as a result in part the newly-
functioning immune system. 
This study is also limited in a number of important ways. Most importantly, our sample 
size was quite small. Moreover, clinical considerations often led to inconsistent 
microbiome sampling based on patient and clinician availability, as sample collection 
was a secondary concern to patient monitoring. As a result, our ability to make broad 
inferences based on this sample set is limited.  
Opportunities to study similar systems of immune system/microbiome dynamics are 
present in SCID patients who undergo hematopoetic stem cell transplantation (HSCT). A 
pilot study looking at the microbiome development in SCID patients after HSCT (Lane, 
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2015) was also performed, though with 16S rRNA gene amplicon sequencing rather than 
shotgun sequencing, no healthy controls, shorter sampling period, and no concurrent TCR 
sequencing. They found inconsistent results in microbiome diversity after transplantation, 
possibly due to the limited temporal range of the study, but did note that there were clear 
differences in the microbiota before and after transplantation in the four subjects they 
studied. 
In summary, these data illustrate some of the uses of multi-omic data in assessing 
outcome in human gene therapy.  As more of these studies are carried out, it will be 
possible to more fully assess the utility of such data.  Of particular interest will be any 
signatures that help forecast outcome and provide new opportunities for initiating specific 
interventions. 
4.5. Methods 
4.5.1. Human subjects 
Patients were recruited as described (M. Cavazzana-Calvo et al., 2000; Hacein-Bey-
Abina et al., 2014). We collected the same sample types from six healthy children 
between the ages of 21-43 months under IRB 13-010072. We obtained sorted CD3+ T 
cells from three anonymous healthy adult donors above the age of 18 from the Human 
Immunology Core at the University of Pennsylvania. All samples were stored at -80oC. 
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4.5.2. Integration site analytical methods 
Integration site sequences were determined using two different methods due to changes in 
technology over the period of patient monitoring.  In the first, 454/Roche pyrosequencing 
was used to determine integration site placement (G. P. Wang et al., 2007).  In the 
second, Illumina paired end sequencing was used (C. C. Berry et al., 2012; C. C. Berry et 
al., 2017; Hacein-Bey Abina et al., 2015; Sherman et al., 2017). In both, DNA was 
broken using shearing or restriction enzyme cleavage, then DNA adaptors ligated on to 
the broken DNA ends.  Nested PCR was then used to amplify from the linker to the 
integrated vector, and the intervening segment of human DNA sequenced.  All 
integration site sequence analysis was be carried out in quadruplicate to minimize PCR 
jackpotting. All sample sets were worked up together with human DNA lacking 
integrated lentiviral sequences to monitor for PCR contamination, which was typically 
undetectable. Different linkers were be used for ligation-mediated PCR for each sample 
in a set to block PCR cross over. All samples were bar coded on both ends of the 
molecule, and only those with correct bar code pairs analyzed, thereby suppressing 
artifactual molecules resulting from PCR recombination.  A total of 31 samples were 
analyzed, yielding a total of 24,170 integration sites. 
4.5.3. TCR sequence analysis 
TCR sequencing was performed on whole blood samples that had been fractionated to 
yied T cell (CD3+) or PBMC fractions. Genomic DNA was isolated and sequenced at 
Adaptive Biotechnologies to determine CDR3 region sequences of the TCR beta locus 
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(H. Robins et al., 2012). Data were analyzed using the immunoSeq Analyzer version 3.0. 
A total of 40 samples were analyzed, yielding a total of 32 million TCRB sequences. 
4.5.4. Microbiome sequencing 
DNA was isolated from fecal, oral and nares samples using the following procedures: 
Small aliquots of fecal material (<= 1ml) and the tips of each swab (for oral and nares 
swabs) were deposited into a PowerSoil bead tube. DNA was extracted using standard the 
MoBio PowerSoil DNA extraction protocol, with one or more blank extraction controls 
worked up simultaneously with each set of samples. Work spaces were decontaminated 
using bleach and UV irradiation. The resulting DNA from all samples and blank controls 
was sequenced on an Illumina HiSeq 2500 using NextSeq chemistry and standard 
Illumina dual barcoding for each sample. 
Due to artifacts in genomic sequences for members of the Apicomplexa family, many 
reads from a common water contaminant (Bradyrhizobium) were cross-annotated as 
belonging to Apicomplexa. Consequently we removed all Bradyrhizobium and 
Apicomplexa reads before further analysis due to their uncertain provenance. 
4.5.5. Virome analytical methods 
Viral particles were isolated from a subset of the fecal samples using a protocol adapted 
from (Minot et al., 2013). Fecal samples were homogenized and filtered through a 0.4 
micron filter. The filtered samples were then treated with DNaseI and RNAseI to remove 
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exogenous nucleic acids.  Combined nucleic acids were then purified from the sample 
using the Qiagen UltraSens Virus Kit. 
To obtain DNA viruses, we amplified viral genomes in an aliquot of the combined 
nucleic acids using the Illustra Genomiphi V2 DNA amplification kit. Resulting 
amplified DNA was quantified using PicoGreen and stored at -20oC. To obtain RNA 
viruses, we treated a separate aliquot of the combined nucleic acids with DNAse+ and 
then performed reverse transcription of the RNA to cDNA using the SuperScriptIII First-
Strand Synthesis System from Life Technologies and second strand synthesis using 
Sequenase. The resulting cDNA was quantified with PicoGreen and stored at -20oC. 
Resulting DNA was prepared and sequenced using NextSeq for library preparation and 
an Illumina HiSeq 2500 for sequence acquisition. The same postprocessing pipeline was 
used, including all quality-control, host removal, and read annotation steps. For analysis, 
we considered only reads that fell under the Virus classification, and removed the 
following viral annotations as being reagent contamination (Abbas et al., 2016; Clarke et 
al., 2017): Enterobacteria phage M13, Enterobacteria phage T7, Enterobacteria phage 
phiX-174 sensu lato, Bacillus phage phi29, and Pseudomonas phage phi6, human 
herpesvirus 6 and 7, and Shamonda virus. 
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4.5.6. Bioinformatic methods 
To estimate population sizes of T cell progenitors from integration sites we used a 
jackknifed Chao1 estimator (abundance-based), and for TCR sequence data, we used the 
incidence-based Chao2 estimator (Chao, 1987). 
Sequence reads for all metagenomic samples were processed using the Sunbeam pipeline 
(https://github.com/eclarke/sunbeam). Reads were quality-controlled by trimming low-
quality bases and adapter sequences using Trimmomatic (Bolger et al., 2014), and host 
reads were removed using BWA (Li & Durbin, 2010). The remaining reads were filtered 
for low-complexity sequences using dustmasker (Camacho et al., 2009) and Komplexity 
(https://github.com/eclarke/komplexity). The reads that remained were assigned 
taxonomy via Kraken (Wood & Salzberg, 2014) and a custom database built on all 
microbial genomic sequences in RefSeq release 79 (O'Leary et al., 2016).  
Antibiotic resistance gene levels were assessed using ShortBRED (Kaminski et al., 2015) 
and a marker gene database built from CARD (Jia et al., 2017) available on the 
ShortBRED website 
(https://bitbucket.org/biobakery/shortbred/downloads/ShortBRED_CARD_2017_markers
.faa.gz). The same reads used as input to the Kraken taxonomic classifier were used as 
input to ShortBRED.  
Final analysis and figure generation was performed using the R statistical software (R 
Core Team, 2017). Bray-Curtis dissimilarity and other ecological metrics were calculated 
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using the R package vegan (Dixon, 2003). The full code listing and post-processed data 
used for analysis and figures is available online at https://github.com/eclarke/scid-
multiomics-paper.  
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4.7. Supplemental Material 
4.7.1. Supplemental Figures 
 
Supp. Figure 4-1. PBMC samples timeline. 
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Supp. Figure 4-2. Genes near integration sites. 
Stacked bar graphs summarizing genes at or near integration sites for each subject and sample studied here. 
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Supp. Figure 4-3. TCRB population characteristics (PBMC). 
Stacked bar graphs summarizing characteristics of the TCRB repertoire sequenced from PBMC cells. 
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Supp. Figure 4-4. TCRB repertoire similarity (PBMC). 
Bray-Curtis dissimilarity measurements for the TCRB repertoires sequenced from PBMC cells. 
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Supp. Figure 4-5. Lymphocyte progenitor cell divisions. 
Population size estimates for progenitors and daughter t cells, with the minimum number of doublings (cell 
divisions) required. 
 
 
 143 
 
 
Supp. Figure 4-6. Mean read counts for metagenomic sequencing. 
 
4.7.2. Supplemental Tables 
All supplemental tables are attached in the Digital Supplement named 
SupplementalTables.xlsx. 
Supp. Table 4-1. Subjects in this study. 
Supp. Table 4-2. Vector integration site data. 
Supp. Table 4-3. TCR-beta repertoire data. 
Supp. Table 4-4. Microbiome data  
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Chapter 5. Conclusions and Future Directions  
In this thesis I describe novel approaches to using metagenomic sequencing in idiopathic 
and immune-related diseases. Metagenomics has found fruitful application in studies 
involving gastrointestinal disorders and dysbiosis of existing communities. However, the 
utility of metagenomics has been less clear in other types of diseases. The heightened 
sensitivity of next-generation sequencing at retrieving rare microbes will be key to 
uncovering causal pathogens in idiopathic diseases, but standard approaches suffer from 
extreme sensitivity to contamination and false-positives (Lauder 2016). Meanwhile, the 
interactions between microbiota and the immune system are beginning to be more clearly 
understood (Arpaia 2013, Kamada 2014, Atarashi 2013) but their interplay in immune 
disorders is less clearly defined. 
In Chapter 2, I present a study where we looked for microbial triggers of sarcoidosis, a 
granulomatous disease with no known cause. Our effort involved experimental and 
statistical methods to rigorously account for environmental contamination. We collected 
paired environmental controls for every sample and specific for every sample type: for 
formalin-fixed, paraffin-embedded (FFPE) tissue we sampled the surrounding blank 
paraffin, while for bronchoalveolar lavage (BAL) we sampled the prewash rinse of the 
scope done prior to the procedure. These paired environmental controls were integrated 
into the differential abundance testing by the use of a generalized linear mixed model 
(GLMM) in which the background level of a taxa was allowed to vary in each sample 
pair.  
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This approach demonstrated exceptional precision in the face of strong environmental 
covariates. We found that in one set of FFPE tissue samples, high levels of Aspergillus 
fungi were present in sarcoidosis samples and not in healthy controls. But this same 
difference was seen in the paired environmental controls, indicating that Aspergillus was 
environmentally derived. (We later traced the source of this contamination back to 
difference in storage sites between the two sample groups.) In studies without this 
experimental design, we would have been unable to disentangle the environmental 
confounder from the study group and spent significant time investigating Aspergillus 
fungi as potential sarcoidosis triggers. However, differential abundance testing with the 
GLMM did not identify Aspergillus as enriched. Rather, it identified a different fungus in 
the Cladosporiaceae family as being enriched in sarcoidosis tissue over both healthy 
tissue and the background environment. Cladosporiaceae fungi, while not known to be 
pathogenic, are significant allergens and can cause disorders including hypersensitivity 
pneumonitis (Chiba et al., 2009; Silva & Ekizlerian, 1985), so this is a biologically 
plausible trigger in accordance with Relman’s postulates (Fredricks & Relman, 1996). 
This paired environmental control study design and associated model are applicable to 
other low-biomass metagenomic studies that aim to find differences between two groups. 
While consensus has been reached on the necessity of blank controls in these studies to 
characterize the input from reagents (Kim et al., 2017; Salter et al., 2014), those controls 
alone are not always sufficient–for instance, they would not have uncovered the 
Aspergillus contaminant as described above. There exist other approaches for 
determining the source of microbial signatures in a sample (Knights et al., 2011), but this 
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is the first able to translate these contaminating sources into terms that affect differential 
abundance testing. Many clinical studies would benefit from this approach, especially 
those that investigate microbial communities in sources previously considered sterile in 
healthy individuals, such as the brain or placenta. In these studies, collection and storage 
methods may contribute significant amounts of microbial biomass as a percentage of the 
total. Without the controls, researchers may be erroneously reporting the presence of 
endogenous or enriched microbiota when in fact they are subtle contaminants. 
 In Chapter 3 I describe a computational method that efficiently designs primers to 
selectively amplify a target’s genome from a complex mixture. This program, swga, 
makes the method described in (Leichy 2014) significantly more accessible to a broad 
range of researchers. The wet-side method, selective whole-genome amplification 
(SWGA), uses a set of phi29 primers that bind more frequently to a target’s genome than 
the background to preferentially amplify the target using multiple-displacement 
amplification. With the correct primers, the resulting amplicon will have much higher 
amounts of target DNA proportionally than the starting mixture. Consequently, less 
sequencing effort is required to achieve high depth-of-coverage of the target genome. The 
swga program described in this chapter makes it possible to rapidly design primer sets for 
this assay, which was originally a manual and error-prone process. The program works 
by first identifying all k-mers of a range of lengths in the target and background genome. 
It then filters the k-mers for undesirable characteristics including self-complementarity 
and suboptimal melting temperature range, or uneven binding on the target genome. It 
then assembles a graph representation with primers as vertices, and compatible primers–
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i.e. those that do not form primer dimers–are linked by edges. Each primer is weighted by 
how frequently it binds the background genome. The program then searches for cliques, 
or completely-interconnected subgraphs, with the smallest possible weight. These cliques 
form the basis for selective primer sets for the SWGA method.  
In this chapter, I demonstrated the efficacy of this program and approach on three real-
life host/parasite systems. SWGA, when used with a well-chosen primer set, significantly 
reduces the costs associated with repeatedly obtaining high-coverage genomes of a given 
target. This is especially critical when retrieving genomes from targets that are difficult or 
impossible to culture, especially in the context of pathogen or parasite genomics. In this 
sense it is complementary to our efforts in Chapter 2 to identify microbial agents in 
sarcoidosis: one possible use for SWGA is the isolation and characterization of the 
precise Cladosporiaceae fungi in the sarcoidosis samples to see if there are strain-level 
differences that may be causing disease symptoms. 
In Chapter 4, I presented our efforts to characterize the interactions between the 
microbiome and immune system of SCID patients after gene therapy. The gene therapy 
trials for SCID provided a unique opportunity to observe a cohort of humans born 
without an immune system, but with colonized microbiomes (normally, the microbiome 
and immune systems co-develop in healthy babies). Once the gene therapy was 
administered, these patients’ immune systems began to develop, and we were able to 
track how the immune system and microbiome in these patients changed in response to 
each other. To do this, we used T cell repertoire sequencing and metagenomic shotgun 
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sequencing on a longitudinal sample set. We found that patients generally reconstituted a 
normal-looking immune system when the therapy worked, which was concordant with 
reported positive clinical outcome. We also found that patients’ microbiomes often 
started off in a dysbiotic state, frequently characterized by the dominance of certain 
bacteria or viruses, but shifted to resemble healthy children as time went on. We also 
found that the microbiomes of these patients began to harbor higher levels of antibiotic 
resistance genes as time went on, up until around six months post-therapy. This likely 
correlates to high exposure levels of antibiotics administered prophylactically until the 
patients were no longer immunocompromised (around six months post-therapy). We also 
found high levels of adenovirus and astrovirus in these patients, which only occasionally 
corresponded to clinical reports. In each case, high viral loads subsided with time, 
indicating clearance of the virus. 
This chapter demonstrated the potential applications for metagenomics in immune 
diseases and gene therapy. Because of established links between the microbiome and 
immune system, diseases that affect the immune system like SCID are likely to affect the 
immune system (and vice versa). In SCID patients, we were unsure whether immune 
system restoration would lead to restoration of a normal microbiome, or if a dysbiotic 
state would persist due to a founder-type effect. In the patients for which we had the 
longest sampling time course, we did see a normalization of the microbiome and decrease 
of antibiotic resistance load after immune reconstitution. While this conclusion is limited 
by the small number of patients, it suggests that the immune system acts to maintain a 
healthy microbial community in these patients. 
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Future directions 
The work presented in this thesis center around the use of metagenomic sequencing in a 
variety of diseases. I explored the use of sequencing to robustly identify triggers in 
sarcoidosis, efficiently isolate difficult-to-culture pathogen genomes such as 
Mycobacterium tuberculosis using SWGA, and characterize microbe-immune 
interactions in SCID after gene therapy. These works center around short-read 
sequencing, the current state-of-the-art sequencing method used today for metagenomics. 
However, it seems likely that this will soon be supplanted by rising long-read 
technologies, such as those from Pacific Biosciences and Oxford Nanopore. 
The essence of nanopore long-read sequencing is a small pore that moves nucleotide 
molecules through a few bases at a time and measures changes in the electrical potential 
based on the sequence. It avoids issues inherent to Illumina chemistry that lead to high 
error rates with longer sequences, and consequently can read tens of kilobases in length 
per sequence (under optimal conditions). However, nanopore sequencing comes with its 
own drawbacks, including a higher error rate and more difficult-to-model error profile. 
Even in the last few years, however, the error rates have decreased substantially and it 
seems reasonable to expect them to continue falling. Another key benefit of nanopore 
sequencing, specific to the Oxford minION, is the extremely small size of the sequencer 
itself. It is only slightly larger than a thumb drive and connects to a computer using USB. 
This small size raises alluring potential for field deployment as part of a portable 
sequencing and analysis toolkit. 
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Metagenomically, long-read sequencing offers a number of advancements over current 
methods. First, the retrieval of long contiguous DNA allows us to fill in the gaps and 
reconstruct microbial genomes much more easily (Loman, Quick, & Simpson, 2015; 
Quick et al., 2017). More comprehensive microbial genome databases will significantly 
improve our ability to classify and functionally annotate microbiomes. Second, long 
reads offer the ability to recover strain-level resolution in tagged sequencing experiments. 
While we are nominally constrained to tagged sequences smaller than 500bp in Illumina 
paired-end sequencing, long reads would enable the recovery of the entire 16S or ITS 
region and significantly improve our phylogenetic resolution (Kerkhof, Dillon, 
Häggblom, & McGuinness, 2017). Third, it opens up new opportunities for 
biosurveillance. Assuming we could identify a specific sequence unique to a pathogen or 
virulence gene of interest, long read sequencers can “read until” detection of that 
sequence (Loose, Malla, & Stout, 2016). Paired with a potentially field-deployable 
sequencer, this could enable extremely rapid monitoring of an environment for pathogens 
and antibiotic resistance capabilities, without the need for culture, extensive 
bioinformatics analysis, or data storage. 
Even considering our current approaches in short-read sequencing, there remains 
significant room for advancement from the techniques outlined in this thesis. 
Metagenomic sequencing is exquisitely sensitive, but this can result in a higher level of 
false positives and spurious detections. In Chapter 2, I outlined an experimental approach 
that helps assuage these problems, but there are situations in which environmental 
controls may not be identifiable or obtainable. Approaches that restrict DNA to just those 
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from viable organisms may be worthwhile in certain studies (Emerson et al., 2017) but 
often samples are collected and stored in ways that damage or kill the microbes in them. 
Other ways of reducing spurious detections include the use of RNA in conjunction with 
DNA, on the premise that RNA is more readily degraded in the environment due to 
ubiquitous RNase activity. Making cDNA libraries from RNA and comparing to the 
results from gDNA could identify signatures from only authentically-present microbes in 
the original sample.   
It is likely that metagenomic sequencing will become a core part of diagnostic and 
clinical work in time, but it has some way to go before it reaches the necessary level of 
affordability, speed and rigor. The promise of rapid, unbiased detection of any microbe or 
gene in a sample is one that could revolutionize our ability to track pathogens and disease 
outbreaks. Similarly, integration of metagenomic sequencing with new advancements in 
immunological sequencing will allow us to more effectively treat and understand 
immunological diseases. In total, the work demonstrated in this thesis lays a foundation 
for more robust and informative uses of metagenomic sequencing in the study of 
idiopathic and immunological disorders.  
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